Profiling cerebrovascular function in migraine: A systematic review and meta-analysis

Journal of Cerebral Blood Flow & Metabolism 2021, Vol. 41(5) 919–944 © The Author(s) 2020 Article reuse guidelines: sagepub.com/journals-permissions DOI: 10.1177/0271678X20964344 journals.sagepub.com/home/jcbfm



Jemima SA Dzator¹, Peter RC Howe^{1,2,3} and Rachel HX Wong^{1,2}

Abstract

Previous studies have investigated whether migraine is a circulatory disorder, as migraineurs are at heightened risk of cerebrovascular disease. However, in most cases, systemic vascular function was evaluated, which may not reflect abnormalities in the cerebral circulation. Therefore, we aimed to determine whether cerebrovascular function differs between migraineurs and controls. A systematic literature search was conducted across three electronic databases to search for studies that compared cerebrovascular function in migraineurs to controls. Where applicable, meta-analyses were used to determine standardised mean differences (SMD) between migraineurs and controls. Seventy articles were identified, 40 of which contained quantitative data. Meta-analyses showed pulsatility index (PI) was higher (SMD = 0.23; 95%CI = 0.05 to 0.42, P = 0.01) and cerebrovascular responsiveness (CVR) to hypercapnia was lower (SMD=-0.34; 95%CI=-0.67 to -0.01, P = 0.04) in the posterior circulation of migraineurs, particularly those without aura. The meta-analyses also indicated that migraineurs have higher resting mean blood flow velocity in both anterior (SMD = 0.14; 95%CI = 0.05 to 0.23, P = 0.003) and posterior circulations (SMD = 0.20; 95%CI = 0.05 to 0.34, P = 0.007). Compared to healthy controls, migraineurs have altered cerebrovascular function). Future studies should investigate whether improvement of cerebrovascular function is able to alleviate migraine.

Keywords

Cerebral blood flow, cerebrovascular function, cerebrovascular responsiveness, neurovascular coupling, pulsatility index

Received 19 June 2020; Revised 26 August 2020; Accepted 15 September 2020

Introduction

Migraine is a primary headache disorder associated with significant physical, psychosocial and emotional disability.¹ Estimated to affect one in 10 people world-wide, migraine is characterised by a severe, throbbing, often unilateral headache that can last for up to three days.² A typical migraine attack can be divided into four main phases, viz. prodromal, aura, headache and postdromal. However, not all migraineurs experience every phase of a typical migraine attack.³ There are two main types of migraine: migraine with aura and migraine without aura, the latter subtype being the more common of the two.⁴ Additionally, migraine can be subdivided into two categories based on the frequency of migraine. Chronic migraine is

characterised by headaches occurring on 15 or more days per month, whereas episodic migraine is characterised by headaches that occur on 14 or fewer days per month.⁵

¹Clinical Nutrition Research Centre, School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, Australia
²Centre for Health Research, Institute for Resilient Regions, University of Southern Queensland, Springfield Central, Queensland, Australia
³UniSA Allied Health & Human Performance, University of South Australia, Adelaide, Australia

Corresponding author:

Rachel HX Wong, Clinical Nutrition Research Centre, School of Biomedical Sciences and Pharmacy, University of Newcastle, NSW 2308, Australia.

Email: Rachel.Wong@newcastle.edu.au

Migraine pathophysiology

Despite its high prevalence, the pathophysiology of migraine is yet to be completely elucidated. A current hypothesis of migraine involves activation of the trigeminovascular system (TVS), comprising sensory neurons that originate from the trigeminal ganglion and innervate blood vessels of the meninges (such as the middle meningeal artery) and cerebral arteries (such as those that form the Circle of Willis).⁶ Activation of the TVS is believed to trigger the release of vasoactive neuropeptides (namely substance P, neurokinin A, pituitary adenylate-cyclase activating peptide and calcitonin gene-related peptide) from trigeminal nerve fibres onto cerebral and meningeal blood vessels, subsequently resulting in transient vasodilation, plasma protein extravasation and acute neurogenic inflammation of the vessels. The neurogenic inflammation and vasodilation of cerebral and meningeal blood vessels may trigger mechanical and chemical stimulation of neighbouring nociceptors, resulting in migraine pain and the further release of vasodilatory and inflammatory neuropeptides; thus, perpetuating the migraine pain cycle.^{6,7} Activation of the TVS is central to the current theory of migraine; however, what causes the initial activation in migraine is unknown.

Endothelial dysfunction and migraine

There has been conflicting evidence as to whether migraine is associated with endothelial dysfunction. A crucial function of the endothelium is to regulate the vasomotor tone; if compromised, both vasodilatation and vasoconstriction may be impaired.⁸ To see whether endothelial dysfunction is associated with migraine, Sacco et al.⁹ reviewed studies that examined systemic endothelial function, as measured by flow-mediated dilatation, endothelial progenitor cells and arterial tonometry. The findings from these studies were inconsistent, with reports of lower, higher or no difference in systemic endothelial function of migraineurs when compared to that of controls.⁹ However, systemic vascular abnormalities may not necessarily reflect cerebrovascular pathology.^{10–12} Recently, Ornello et al.¹³ investigated whether migraine was associated with poor cerebrovascular function: however, findings from their narrative review, which assessed cerebrovascular reactivity to hypercapnia or hypocapnia, were conflicting. As such, it is still not clear if migraineurs have abnormalities of cerebrovascular function, which could partially account for their heightened risk of cerebrovascular diseases, such as stroke. Hence, the aim of this systematic review and meta-analysis is to determine whether migraine is associated with altered cerebrovascular function by summarising the findings of original studies that have compared cerebrovascular function in migraineurs to that of controls.

Methods

Search strategy and inclusion/exclusion criteria

A systematic literature search was conducted using three electronic databases (EMBASE, Medline and Web of Science) to search for full text, original studies that compared cerebrovascular function in migraineurs to controls until July 2020. The following search terms were used: "migraine" or "headache" AND "brain" or "cerebral" AND "endothelial" or "blood flow". Other inclusion criteria were studies conducted in adult humans, studies conducted in the migraine-free period and studies published in English. Studies that assessed cerebrovascular function in migraineurs and controls as part of an intervention trial were included if they provided baseline cerebrovascular function data. Additionally, the reference lists of relevant studies were scanned to identify any studies that may have been missed during the initial search. Studies were excluded if they assessed cerebrovascular function during a migraine attack, if they did not compare cerebrovascular function in migraineurs to controls and/or if they were not published in English. Abstracts, case reports, letters, notes, reviews and surveys were also excluded.

Data extraction and analysis

Data extraction was performed by one investigator using a standardised data extraction form. Data extracted from the articles that met the eligibility criteria for the qualitative analysis comprised the study population and migraine subtype(s), the blood vessel (s) or brain region(s) where cerebrovascular function was assessed, whether cerebrovascular function was assessed at rest or under dynamic conditions, the metric used to assess cerebrovascular function and key findings. Data extracted from the articles that met the eligibility criteria for the quantitative analysis included the mean and standard deviation for each relevant measure of cerebrovascular function and the sample size of the migraineur and control groups.

Quality assessment

A modified Newcastle-Ottawa scale (NOS) for crosssectional studies was used to assess and evaluate the methodological quality of studies included in the meta-analyses. The maximum score for the modified NOS was nine where scores between 0 and 3, 4 and 6 and 7 and 9 were categorised as low, moderate and high quality respectively.

Data analysis and statistical methods

Meta-analyses of data were performed where applicable using a random-effects model in Review Manager (RevMan) for Windows, version 5.4.0 (The Cochrane Collaboration, 2020) to determine standardised mean differences (SMD) between migraineurs and controls. To be included in the meta-analyses, studies had to provide sufficient data in order for the SMD of the cerebrovascular function metric between migraineurs and controls to be calculated. As cerebrovascular function was assessed in many different cerebral blood vesand brain regions, relevant measures sels of cerebrovascular function were grouped into the anterior and/or posterior circulations or similar brain regions for meta-analyses, where applicable. The I^2 statistic was used to estimate the heterogeneity between studies, where values of 25%, 50% and 75% represent low, medium and high heterogeneity, respectively.14 Publication bias was assessed through visual examination of the funnel plots and Egger's regression test was used for meta-analyses that included 10 or more studies. Duval and Tweedie's trim-and-fill method was used to estimate any additional studies for meta-analyses bias.15 were found to have publication that Comprehensive meta-analysis (CMA Software, Version 3.3.070) was used for the Egger's regression test and Duval and Tweedie's trim-and-fill. For all analyses, a *P* value of <0.05 was considered statistically significant.

Subgroup analysis

We performed subgroup analyses for the different subtypes of migraine, which included migraine with aura, migraine without aura, chronic migraine and episodic migraine. Additionally, subgroup analysis was performed for a mixed subgroup for studies that did not perform separate analyses for migraineurs based on their aura status or frequency of migraine.

Results

Study selection

The database search and other sources yielded 2307 articles (see Figure 1). After duplicates were removed, 2128 articles remained and were subsequently screened for relevance by examining the article title and abstract. In total, 2054 articles were excluded after screening for relevancy leaving 74 full text articles to be assessed for eligibility. Four articles did not meet the inclusion criteria, as there was no control group. In total, 70 articles met the eligibility criteria and were included in the qualitative analysis and 40 articles were included in the quantitative analysis.

Study characteristics

Characteristics of each study are summarised in Table 1. Fifty-five studies identified from the literature search used Transcranial Doppler (TCD) ultrasound to measure cerebral blood flow velocity (CBFV) in resting and/or dynamic conditions. Cerebral arteries that were assessed using TCD ultrasound included those that form the anterior circulation, viz. anterior cerebral artery (ACA) and middle cerebral artery (MCA) and those that form the posterior circulation, viz. basilar artery (BA), posterior cerebral artery (PCA) and vertebral artery (VA). Three studies also assessed cerebrovascular function of the internal carotid artery (ICA).

Other methods that were used to assess cerebrovascular function included the following: functional magnetic resonance imaging (fMRI) which was used by eight studies; near infrared spectrometry (NIRS) which was used by three studies and single-photon emission computerized tomography (SPECT) which was used by six studies. The main regions of the brain where cerebrovascular function was assessed included the frontal lobe, occipital lobe, parietal lobe, temporal lobe, primary somatosensory cortex, primary visual cortex, postcentral gyrus and the frontotemporal region. Two studies assessed the cerebrovascular function in grey matter, white matter and globally.

Cerebrovascular function assessed using TCD ultrasound

Mean blood flow velocity. Thirty-five studies were identified from the literature search that compared resting mean blood flow velocity (MBFV) in migraineurs to controls;^{12,16–49} 30 studies assessed MBFV in the anterior circulation.^{12,19–24,26–32,34–49} All but four studies found no significant difference in MBFV in the anterior circulation between migraineurs and controls; Abernathy et al., Fiermonte et al., Karadas et al. and Kastrup et al. found migraineurs to have higher MBFV in the anterior circulation.^{21,34,35,41}

Figure 2 shows a forest plot of mean differences in MBFV in the anterior circulation between 67 migraine subgroups (n=2357) and their respective controls (n=2053). Heterogeneity between comparisons was low ($I^2=47\%$) and MBFV (SMD=0.14; 95%CI 0.05 to 0.23; P=0.003) was significantly higher in migraineurs.

Sixteen studies compared MBFV in the posterior circulation of migraineurs and controls.^{12,19–21,23–26,29,33,35,41,45–47,49} Abernathy et al., Chernyshev et al. and Karadas et al. found migraineurs to have higher MBFV in the posterior circulation compared to controls;^{21,33,41} the remaining 13 studies were not able to



Figure 1. PRISMA flow diagram of selection of studies for quantitative and qualitative analysis.

detect a significant difference in MBFV between migraineurs and controls.^{12,19,20,23–26,29,35,45–47,49}

Figure 3 shows a forest plot of mean differences in MBFV in the posterior circulation between 39 migraine subgroups (n = 1855) and their respective controls (n = 1290). Heterogeneity between comparisons was moderate (I²=68%) and MBFV was significantly higher in migraineurs (SMD=0.20; 95%CI 0.05 to 0.34; P = 0.007).

Pulsatility index. The pulsatility index (PI) is used as a measure of stiffness of a blood vessel; a higher PI correlates with a stiffer blood vessel. PI is calculated as follows: PI = (maximum BFV-minimum BFV)/MBFV.

Twelve studies were identified from the literature search that used TCD ultrasound to compare PI in the anterior circulation of migraineurs and controls.^{16,17,23,28,30,32,33,39,40,44–46} Nine of these studies found no significant difference in PI between migraineurs and controls.^{16,17,23,28,30,32,39,44,46} Chernyshev et al. and Totaro et al. found migraineurs to have significantly higher PI in the anterior circulation compared to controls;^{33,45} Fiermonte et al. were the only study to find migraineurs to have lower PI than controls.⁴⁰

Figure 4 shows a forest plot of mean differences in PI in the anterior circulation between 21 migraine subgroups (n = 656) and their respective controls (n = 750). Heterogeneity between comparisons was low ($I^2=36\%$) and there was no significant difference in PI between migraineurs and controls (SMD=-0.02; 95%CI -0.16 to 0.13; P = 0.83).

Five studies compared PI in the posterior circulation of migraineurs to controls; no significant difference in PI between migraineurs and controls was reported.^{17,23,33,45,46}

Figure 5 shows a forest plot of mean differences in PI in the posterior circulation between 13 migraine

Study	Population and numbers	Area of assessment	Assessment	Key findings	NOS
TCD Studies					
Altamura et al. ⁵¹	Total = 129 MA = 56 (46 F/10M) Stroke = 20 (9 F/11M) Controls = 53 (42 F/11M)	Unilateral MCA (left) Unilateral PCA (right)	CVR to BHT (30s breath hold)	MA had a higher BHI compared to controls (and stroke patients).	8
Lee et al. ⁵⁶	(1217111) Total = 353 MX = 248 (201 F/47M) Controls = 105 (86 F/19M)	BA Bilateral MCA Bilateral PCA	CVR to BHT (30s breath hold)	MX had a lower BHI compared to controls.	8
Altamura et al. ⁸⁷	Total = 70 MA = 39 (34 F/5M) Stroke = 15 (8 F/7M) Controls = 16 (8 F/8M)	Unilateral MCA (left) Unilateral PCA (right)	CVR to BHT (30s breath hold)	MA had a higher BHI compared to controls (and stroke patients).	5
Gollion et al. ⁵²	Total = 44 MA = 22 (18 F/4M) Controls = 22 (17 F/5M)	Unilateral MCA (right)	CVR to BHT (30s breath hold) Cerebral autoregula- tion (Dx, Mx, phase, gain)	No difference. No difference.	8
Karacay Ozkalayci et al. ¹⁷	Total = 75 MA = 10 (MD) MO = 30 (MD) TTH = 10 (MD) Controls = 25 (17 F/8M)	Bilateral ACA BA Bilateral MCA Bilateral PCA Bilateral VA Bilateral MCA	Resting MBFV	No difference.	7
Podgorac et al. ¹⁶	Total = 273 $MA = 100 (71 F/29M)$ $MO = 70 (61 F/9M)$ $TTH = 38 (21 F/17M)$ $CH = 35 (10 F/25M)$ $Controls = 30$ $(13 F/17M)$		CVR to BHT (30s breath hold) Resting MBFV	MA had a higher BHI compared to controls. No difference.	8
Choi et al. ¹⁸	Total = 84 EM = 28 (24 F/4M) RCVS = 28 (24 F/4M) Controls = 28 (25 F/ 3M)	BA Bilateral MCA Bilateral PCA	CVR to BHT (30 s breath hold) Resting MBFV	MD. MD.	8
Gonzalez- Quintanilla et al. ⁵³	Total = 113 CM = 35 (31 F/4M) EM = 37 (27 F/10M) Controls = 41 (29 F/12M)	BA Bilateral MCA	CVR to BHT (breath hold time not specified)	CM and EM had a lower BHI compared to controls.	7
Akgun et al. ¹⁹	Total = 60 CM = 31 (MD) Controls = 29 (MD)	Bilateral MCA Bilateral PCA	CVR to BHT (30s breath hold) Resting MBFV	CM had a lower BHI compared to controls. No difference.	6
Fabjan et al. ²⁰	Total = 52 MX = 29 (21 F/8M) Controls = 23	Unilateral MCA (left) Unilateral PCA (right)	Neurovascular cou- pling (photic stimulation)	MD.	7
Rajan et al. ¹²	(13 F/ IUM) Total = 89 MX = 45 (36 F/9M) Controls = 44 (31 F/13M)	BA Bilateral MCA Bilateral PCA	Resting MBFV CVR to BHT (30s breath hold)	No difference. MX had a lower BHI in BA, left PCA and right PCA compared to controls.	7
	()		Resting MBFV	No difference.	

 Table 1. Cerebrovascular function in migraineurs compared to controls during the migraine free period.

Study	Population and numbers	Area of assessment	Assessment	Key findings	NOS
Karadas et al. ²¹	Total = 40 MA = 20 (15 F/5M) Controls = 20 (16 F/	Bilateral MCA Bilateral PCA	CVR to BHT (100s breath hold)	MA had a higher BHI in the MCA and PCA	8
	4M)		Resting MBFV	MA had a higher MBFV in the MCA and PCA	
Quirico et al. ²²	Total = 30 $MO = 16 (MD)$	Unilateral MCA (right)	Resting MBFV	compared to controls. No difference.	N/A
Reinhard et al. ²³	Controls = 14 (MD) Total = 69 MA = 17 (12 F/5M) MO = 17 (13 F/4M) Controls = 35 (26 F/ 9M)	Unilateral MCA (left) Unilateral PCA (right)	Resting MBFV, PI Cerebral autoregula- tion (phase, gain, Dx)	No difference. MA had higher Dx than controls in the MCA.	7
Min et al. ²⁵	Total = 36 MA = 22 (14 F/8M) Controls = 14 (9 F/5M)	Bilateral PCA	Neurovascular cou- pling (20 s photic stimulus, then 20 s rest for 10 cycles)	No difference.	6
Perko et al. ²⁴	Total = 60 MA = 20 (16 F/4M) MO = 20 (16 F/4M) Controls = 20 (16 F/	Unilateral MCA (right) Unilateral PCA (left)	Resting MBFV CVR to L-arginine infusion (assessed 30 min after infusion)	No difference. MX had a lower CVR in the PCA.	8
Sousa et al. ⁵⁸	4M) Total = 284 MX = 228 (189 F/39) Controls = 56 (31 F/ 25M)	Bilateral MCA	CVR to BHT(30s breath hold)	No difference. MX had a higher BHI compared to controls.	N/A
Wallasch et al. ⁷⁰	Total = 120 MX = 60 (50 F/10M) Controls = 60 (MD)	Bilateral MCA	Cerebral autoregula- tion (CVR to the Valsalva manoeuvre)	MX had a higher CVR to the Valsalva manoeuvre	N/A
El-Khawas et al. ²⁶	Total = 41 MX = 27 (23 F/4M) Controls = 14 (9 F/5M)	Bilateral MCA Bilateral PCA	CVR to hyperventila- tion (3-min hyperventilation) Resting MBEV	MX had a lower CRI.	9
Wolf et al. ⁶⁷	Total = 110 MA = 70 (70 F/0M) Controls = 40 (30 F/ 10M)	Bilateral PCA	Neurovascular cou- pling (photic stimulation)	MX had a higher VEFR ((MBFV during stimula- tion – MBFV at rest)/ MBFV at rest×100) compared to controls	8
Zaletel et al. ⁶⁸	Total = 70 MA = 14 (MD) MO = 16 (MD) Controls = 40 (21 F/ 19M)	Unilateral MCA (left) Unilateral PCA (right)	Neurovascular cou- pling (photic stimulation)	MA and MO had a higher VEFR compared to controls.	N/A
Arjona et al. ²⁸	Total = 131 MO = 36 (26 F/10M) TTH = 51 (32 F/19M) Controls = 44 (25 F/ 19M)	Bilateral MCA	Resting MBFV, PI CVR to BHT (15-45 s breath hold)	No difference. No difference.	8
Reinhard et al. ²⁷	Total = 94 MX = 19 (14 F/5M) Controls = 75 (33 F/ 42M)	Bilateral MCA	Resting MBFV Cerebral autoregula- tion (Dx, Mx, phase, gain)	No difference. No difference.	7

Study	Population and numbers	Area of assessment	Assessment	Key findings	NOS
MüLler and Marziniak ⁶⁹	Total N = 55 MX = 22 (19 F/3M) Controls = 33 (15 F/ 18M)	Bilateral MCA	Cerebral autoregula- tion (gain)	MX had a lower gain compared to controls.	N/A
Zaletel et al. ⁴⁷	Total = 60 MX = 30 (20 F/10M) Controls = 30 (22 F/ 8M)	Unilateral MCA (left) Unilateral PCA (right)	Neurovascular cou- pling (70 s photic stimulation stimulus, 30 s rest)	MX had a higher VEFR compared to controls.	N/A
Backer et al. ⁶⁴	$\begin{aligned} & \text{Total} = 20 \\ & \text{MX} = 10 \text{ (MD)} \\ & \text{Controls} = 10 \text{ (MD)} \end{aligned}$	Unilateral MCA (left) Unilateral PCA (right)	Resting MBFV Neurovascular cou- pling (photic stimulation)	No difference. MX had an exaggerated increase in CBFV at the beginning of the photic stimulation and a delayed decrease to baseline following photic stimulation compared to controls	N/A
Nedeltchev et al. ²⁹	Total = 38 MA = 19 (10 F/9M) Controls = 19 (8 F/ 11M)	Unilateral MCA (right) Unilateral PCA (left)	Neurovascular cou- pling (photic stimu- lation) (10 s stimulus, then 10 s rest for 10 cycles)	MA had a higher ΔMBFV during photic stimula- tion compared to controls.	7
Silvestrini et al. ⁵⁷	Total = 45 MA = 15 (15 F/0M) MO = 15 (15 F/0M) Controls = 15 (15 F/ 0M)	BA Unilateral MCA (left or right side chosen at random)	Resting MBFV CVR to BHT (30s breath hold)	No difference. MA had a lower BHI in BA compared to controls (and MO).	8
Dora et al. ³⁰	Total = 31 MO = 20 (18 F/2M) Controls = 11 (9 F/2M)	Bilateral MCA	CVR to BHT (30s breath hold) Resting MBEV PI	MO had a higher BHI compared to controls. No difference	8
Thomaides et al. ³¹	$\begin{aligned} \text{Total} &= 60 \\ \text{MA} &= 45 \text{ (36 F/9M)} \\ \text{Controls} &= 15 \text{ (12 F/} \\ \text{3M)} \end{aligned}$	Bilateral MCA	Resting MBFV	No difference.	7
Dora et al. ³²	Total = 33 MO = 23 (22 F/IM) Controls = 10 (9 F/IM)	Bilateral MCA	CVR to BHT (30s breath hold) Resting MBFV. Pl	MO had a higher BHI compared to controls. No difference.	N/A
Backer et al. ⁶⁵	Total = 38 MX= 19 (MD) Controls = 19 (MD)	Unilateral MCA (left) Unilateral PCA (right)	Neurovascular cou- pling (3 rounds of 57 s photic stimula- tion, 57 s rest)	MX had a higher initial increase of CBFV fol- lowing the onset than controls in MCA and PCA.	N/A
Chernyshev et al. ³³	Total = 69 RSM = 25 (23 F/2M) LSM = 25 (23 F/2M) Controls = 19 (9 F/ 10M)	BA Bilateral MCA	Resting MBFV, PI	RSM had higher MBFV in the BA and higher PI in the right MCA com- pared to LSM and controls.	9

Study	Population and numbers	Area of assessment	Assessment	Key findings	NOS
Fiermonte et al. ³⁴	Total = 42 MA = 9 (4 F/5M) MO = 12 (8 F/4M) Controls = 21 (MD)	Bilateral MCA	CVR to BHT (breath hold time not speci- fied) and hyperven- tilation (3-min hyperventilation)	MA had a higher CRI to hyperventilation com- pared to controls.	6
			Resting MBFV	MA and MO had higher MBFV compared to controls.	
Heckmann et al. ³⁶	Total = 45 MA = 15 (11 F/4M) MO = 15 (11 F/4M) Controls = 15 (8 F/7M)	MCA (unclear if uni- lateral or bilateral)	Cerebral autoregula- tion (CVR to physi- cal stress) Resting MBFV, RI	MA and MO had a lower ΔRI to physical stress compared to controls. No difference.	7
Kastrup A et al. ³⁵	Total = 50 MX = 20 (16 F/4M) Controls = 30 (17 F/ I 3M)	Bilateral ACA Bilateral MCA Bilateral PCA	CVR to inhalation of 5%CO2 (duration not stated) Resting MBFV	MX had higher CRI in the left ACA, right MCA and right PCA. MX had higher MBFV in	8
				the right ACA and MCA compared to controls.	
Kastrup A et al. ³³	Total = 40 MX = 20 (17 F/3M) Controls = 20 (MD)	Bilateral MCA	CVR to inhalation of 5%CO2 (before metoprolol treat- ment initiated)	No difference.	N/A
Totaro et al. ³⁷	Total = 90 MA = 30 (26 F/4M) MO = 30 (28 F/2M) Controls = 30 (27 F/ 3M)	Bilateral MCA (unclear if unilateral or bilateral)	CVR to inhalation of 5%CO2 (1–2 min inhalation), and hyperventilation (duration not stated)	MO had a lower CRI to CO2 inhalation com- pared to controls.	7
			Resting MBFV	No difference.	
Silvestrini et al. ³⁰	Total = 45	Bilateral MCA	CVR to BHT	No difference.	8
	MA = 15 (11 F/4M) MO = 15 (13 F/2M) Controls = 15 (MD)		(30s breath hold) Resting MBFV	No difference.	
Valikovics et al. ⁶⁰	Total = 31 MX = 12 (MD) Controls = 19 (MD)	Bilateral MCA	CVR to acetazolamide infusion	No difference	7
Fiermonte et al. ⁴⁰	Total = 45 MA = 15 (9 F/6M) MO = 15 (10 F/5M)	Bilateral MCA	CVR to hyperventila- tion (3-min hyperventilation)	MA had a higher CRI than controls.	7
	Controls = 15 (8 F/7M)		Resting MBFV, PI	MA and MO had lower PI than controls.	
Piccini et al. ³⁹	Total = 27 MO = 10 (7 F/3M) TTH = 10 (8 F/2M) Controls = 7 (5 F/2M)	MCA (unclear if uni- lateral or bilateral)	Resting MBFV, PI	No difference.	7
Thomsen et al. ⁶²	Total = 50 MA = 8 (MD) MO = 12 (MD) Controls = 30 (25F/ 5M)	Bilateral MCA	CVR to hyperventila- tion (90 s hyperventilation)	MA had a higher CRI, whereas MO had lower CRI compared to con- trols difference.	7

Study	Population and numbers	Area of assessment	Assessment	Key findings	NOS
Abernathy et al. ⁴¹	Total = 220 MX = 182 (141 F/41M) Controls = 38 (29 F/ 9M)	BA Bilateral ACA Bilateral ICA Bilateral MCA Bilateral PCA Bilateral VA	Resting MBFV	MX had higher MBFV compared to controls.	8
Anzola et al. ⁴³	Total = 60 MX = 30 (22 F/8M) Controls = 30 (18 F/ 12M)	Bilateral MCA	Resting MBFV CVR to hyperventila- tion (1-min hyper- ventilation) and the BHT (30 s breath hold)	No difference. MX had higher CVR to hyperventilation and lower CVR to hyper- capnia compared to controls.	5
Rieke et al. ⁴⁴	Total = 50 MX = 30 (24 F/6M) Controls = 20 (15 F/	Unilateral MCA (ipsi- lateral to migraine)	CVR to inhalation of CO2 (% of CO2 not stated)	MX had lower CVR com- pared to controls.	N/A
	ויוכ		Resting MBrv, PI	MA had higher resting MBFV compared to controls.	
Thomsen et al. ⁴²	Total = 43 MO = 17 (16 F/1M) TTH = 9 (8 F/1M) Controls = 17 (16 F/ 1M)	MCA (unclear if unilateral or bilateral)	Resting MBFV (before nitric oxide infusion)	No difference.	8
Haring and Aichner 46	Total = 60 MA = 17 (MD) MO = 23 (MD) Controls = 20 (14 F/	Bilateral ACA Bilateral MCA Bilateral PCA	Resting MBFV	No difference.	8
Thie et al. ⁶⁶	Total = 23 MX = 11 (MD) Controls = 12 (MD)	Unilateral MCA (left) Unilateral PCA (left)	Neurovascular cou- pling (cognitive and photic stimulation)	MX had higher CVR to photic stimulation, observation of complex images and cognitive tasks compared to controls	N/A
Totaro et al. ⁴⁵	Total = 132 MA = 44 (39 F/5M) Controls = 88 (MD)	BA Bilateral ACA Bilateral MCA Bilateral PCA	Resting MBFV, PI	Migraineurs had higher Pl in the MCA compared to controls.	7
Harer et al. ⁵⁴	Total = 82 IMX = 32 (MD) CMX = 18 (MD) Controls = 32 (MD)	MCA (ipsilateral and contralateral to migraine)	CVR to inhalation of 5%CO ₂	MX had higher CRI com- pared to controls.	N/A
Zwetsloot et al. ⁶³	Total = 65 MO = 48 (MD) Controls = 17 (10 F/ 7M)	BA Unilateral MCA	CVR to hyperventila- tion (I-min hyperventilation)	No difference.	7
Thomas et al. ⁵⁹	Total = 20 MX = 10 (7 F/3M) Controls = 10 (3 F/7M)	Bilateral MCA	CVR to inhalation of 5%CO ₂ (3–6 min inhalation) and hyperventilation (3- min hyperventilation)	MX had higher CVR to inhalation of 5%CO ₂ compared to controls.	N/A

Study	Population and numbers	Area of assessment	Assessment	Key findings	NOS
fMDL Studios				, 0	
Hu et al. ⁷³	Total = 48 CM = 24 (15 F/9M) Controls = 24 (15 F/ 9M)	Angular gyrus Parietal gyrus (inferior, superior) Marginal gyrus (superi- or) Occipital gyrus (superior)	Neurovascular cou- pling (cognitive stimuli)	CM had lower CVR in the left inferior parietal gyrus, superior marginal gyrus and angular gyrus but a higher CVR in the right superior occipital gyrus and superior parietal gyrus.	N/A
Chen et al. ⁷⁸	Total = 30 EM = 15 (11 F/4M) Controls = 15 (11 F/ 4M)	Grey matter Superior temporal gyrus (left hemisphere)	Resting CBF	EM had higher CBF in the left superior temporal gyrus compared to controls.	N/A
Hodkinson et al. ⁷²	Total = 34 MO = 17 (12 F/5M) Controls = 17 (MD)	Primary somatosenso- ry cortex	Resting CBF	MO had higher regional CBF compared to controls.	N/A
Loehrer et al. ⁷⁴	Total = 2489 MX = 456 (365 F/91M) Controls = 2033 (100 F/1933M)	BA Bilateral ICA	Resting CBF	MX had higher CBF in the BA and a higher paren- chymal CBF compared to controls.	N/A
Zhang et al. ⁷⁵	Total = 170 MA = 56 (45 F) MO = 60 (48 F) Controls = 54 (39 F)	Global Grey matter White matter	Resting CBF	No difference.	N/A
Datta et al. ⁷¹	Total = 75 $MA = 25 (21 F/4M)$ $MO = 25 (21 F/4M)$ $Controls = 25 (21 F/ $ $4M)$	Primary visual cortex	Resting CBF	No difference.	N/A
Arkink et al. ⁷⁶	Total = 45 MA = 12 (12 F/0M) MO = 17 (17 F/0M) Controls = 16 (16 F/ 0M)	Frontal gyrus Temporal gyrus Postcentral gyrus	Resting CBF	MA had higher CBF in the frontal gyrus (medial) but lower CBF in the temporal gyrus (inferi- or) and postcentral gyrus. MO had higher CBF in the temporal gyrus (inferior, middle) and lower CBF in the frontal gyrus (inferior).	N/A
Ances et al. ⁷⁷	Total = 10 MM = 5 (5F/0M) Controls = 5 (5F/0M)	Occipital lobe	Neurovascular cou- pling (photic stimu- lation) Resting CBF	MM had a greater increase in cerebral perfusion in response to photic stimulation compared to controls during the mid-follicular phase No difference.	N/A
Schytz et al. ⁸¹	Total = 24 MO = 12 (12 F/0M) Controls = 12 (12 F/ 0M)	Frontal cortex	Neurovascular cou- pling (cognitive stimuli): Stroop task	No difference.	N/A
Akin et al. ⁸⁰	Total = 12 MX = 6 (5 F/1M) Controls = 6 (4 F/2M)	Frontal cortex	CVR to BHT (20s to 30s breath hold)	MX had lower ID and R amplitudes of Hb, tHb and oxygen concentra- tions; therefore lower CVR.	N/A

Study	Population and numbers	Area of assessment	Assessment	Key findings	NOS
Vernieri et al. ⁴⁸	Total = 37 MA = 16 (13 F/3M) Controls = 21 (16 F/	Bilateral MCA Frontotemporal region	CVR to inhalation of $7\%CO_2$ (90s inhalation)	MA had higher CVR compared to controls.	5
	5M)		Resting MBFV	No difference.	
SPECT Studies					
Cheng et al. ⁸⁵	Total = 34 MX = 19 (13 F/6M) Controls = 15 (9 F/6M)	Frontal lobe Occipital lobe Parietal lobe Temporal lobe	Resting CBF	MX had lower parenchy- mal CBF in the frontal, temporal, left parietal and right occipital lobes.	N/A
Meyer et al. ⁸²	Total = 64	Global	Resting CBF	No difference.	N/A
	MX = 37 (25 F/12M) Controls = 27 (11 F/ 16M)	Grey matter (cortical, subcortical) White matter	CVR to oral acetazolamide	MX had higher CVR compared to controls.	
Mirza et al. ⁸⁶	Total = 61 MX = 44 (42 F/2M) Controls = 17 (15 F/ 2M)	Frontal lobe (inferior, superior) Occipital lobe Parietal lobe Temporal lobe	Resting CBF	MX had lower CBF in the superior frontal and occipital lobes.	N/A
Facco et al. ⁸³	Total = 151 $MA = 20 (15 F/5M)$ $MO = 50 (41 F/9M)$ $TTH = 21 (17 F/4M)$ $Controls = 60 (35 F/25M)$	Homologous regions of both the left and right cerebral hemispheres	Resting CBF	MA had lower posterior CBF and lower mean CBF compared to con- trols. MO had higher mean CBF	N/A
Levine et al. ⁸⁴	Total = 47 MA = 15 (MD) MO = 12 (MD) Controls = 20 (MD)	Homologous regions of both the left and right cerebral hemi- spheres (10 anterior probes, 6 posterior probes).	Resting CBF	MA and MO had lower posterior CBF com- pared to controls and lower mean CBF com- pared to controls.	N/A
Benedittis ⁴⁹	Total = 62 MA = 35 (27 F/8M) MO = 13 (7 F/6M) Controls = 14 (8 F/6M)	Bilateral ICA Bilateral MCA Bilateral VA Frontal lobe Occipital lobe Parietal lobe Temporal lobe	Resting CBF, MBFV	No difference.	N/A

ACA: anterior cerebral artery; BA: basilar artery; BHT: breath hold task; CBFV: cerebral blood flow velocity; CRI: cerebral reactivity index; CVR: cerebrovascular responsiveness; ICA: internal carotid artery; LSM: left-sided migraineurs; MA: migraineurs with aura; MBFV; mean blood flow velocity; MCA: middle cerebral artery; MD: missing data; MM: menstrual migraineurs; MO: migraineurs without aura; MX: mix of migraineurs with and without aura; NOS: Newcastle-Ottawa scale; PCA: posterior cerebral artery; PI: pulsatility index;: RI: resistive index; RSM: right-sided migraineurs; TCD: transcranial Doppler; TTH: tension type headache; VA: vertebral artery; VEFR: visually evoked cerebral blood flow response.

subgroups (n = 336) and their respective controls (n = 522). Heterogeneity between comparisons was low ($I^2=38\%$) and PI was significantly higher in migraineurs (SMD = 0.23; 95% CI 0.05 to 0.42; P = 0.01).

Cerebrovascular responsiveness to hypercapnia

Twenty-six studies compared cerebrovascular responsiveness (CVR) to hypercapnia in the anterior and posterior circulations of migraineurs with that of controls. ^{12,16,18,19,21,24,28,30,32,34,35,37,38,43,44,50–60}

Various methods were used to induce hypercapnia: the breath-holding task (BHT), inhalation of carbogen gas, infusion of acetazolamide and infusion of L-arginine. Fourteen studies used the BHT to induce hypercapnia, wherein participants hold their breath for a specified duration, which results in an increase in arterial CO_2 and subsequent vasodilation of cerebral blood vessels.

Study or Subgroup	Mig Mean	raineur SD	s Total	Mean	ontrols SD	Total	Weight	Std. Mean Difference IV, Random, 95% Cl	Std. Mean Difference IV, Random, 95% CI
.1.1 Migraine with Aura									
Altamura (MCA) 2018	68.7	12	39	66.3	12	16	1.4%	0.20 [-0.39, 0.78]	
Altamura (MCA) 2019	68.4	12	56	70.9	16.6	53	2.2%	-0.17 [-0.55, 0.20]	
El-Khawas (MCA) 2010	76.27	13.34	13	75.64	8.85	14	1.0%	0.05 [-0.70, 0.81]	
Fiermonte (MCA) 1995	58.6	9.2	15	55.8	10.6	15	1.1%	0.27 [-0.45, 0.99]	
Flermonte (MCA) 1999	66.03	8.26	47	58.6	9.39	21	0.9%	0.80[-0.01, 1.61]	
Haring (ACA) 1992	00	53.0	17	00	44.7	20	1.370	0.00[0.05, 0.05]	
Hanny (MCA) 1992	50.6	16.6	16	54.0	16.0	15	1.370	0.00 [-0.05, 0.05]	
Kararay Ozkalavri (ACA) 2018	56.1	7 72	10	48 71	8.5	25	1.0%	0.27 [0.43, 0.53]	
Karacay Ozkalavci (MCA) 2018	66 77	8 64	10	61 4	11 97	25	1.0%	0 47 [-0 27 1 21]	2
Karadas (LS. MCA) 2014	61.32	3.58	20	56.94	4.73	20	1.2%	1.02 [0.36, 1.69]	1
Karadas (RS, MCA) 2014	60.77	5.48	20	55.89	4.65	20	1.2%	0.94 [0.28, 1.60]	
Nedeltchev (RS, MCA) 2004	38.4	9.4	19	43.9	18.6	19	1.3%	-0.37 [-1.01, 0.28]	0
Perko (MCA) 2011	74.1	15.7	20	69	10.9	20	1.3%	0.37 [-0.26, 1.00]	11
Podgorac (MCA) 2018	59.4	10.82	100	55.85	11.93	30	2.0%	0.32 [-0.09, 0.73]	
Reinhard (MCA) 2012	60.8	9.4	17	60.7	8	35	1.4%	0.01 [-0.57, 0.59]	
Silvestrini (LS, MCA) 1996	66.3	8.3	15	64	8.2	15	1.1%	0.27 [-0.45, 0.99]	
Silvestrini (RS, MCA) 1996	65.7	9.2	15	65.5	7.3	15	1.1%	0.02 [-0.69, 0.74]	
Totaro (LS, ACA) 1992	48.6	12.3	44	47.4	9.6	88	2.2%	0.11 [-0.25, 0.48]	
Totaro (LS, MCA) 1992	64.8	11.8	44	64.3	12	88	2.2%	0.04 [-0.32, 0.40]	
Totaro (MCA) 1997	64.5	10.4	30	66.3	9.3	30	1.7%	-0.18 [-0.69, 0.33]	
Totaro (RS, ACA) 1992	48.2	14.5	44	47.3	11.3	88	2.2%	0.07 [-0.29, 0.43]	
Totaro (RS, MCA) 1992	66.5	12	44	63.7	10.6	88	2.2%	0.25 [-0.11, 0.61]	
Subtotal (95% CI)			033			180	33.5%	0.19 [0.06, 0.32]	•
Heterogeneity: Tau* = 0.02; Chi* = 21 Test for overall effect: Z = 2.82 (P = 0	8.74, df = 1.005)	22 (P =	0.15);	I*= 239	b				
1.1.2 Migraine without Aura									
Akgun (MCA) 2015	58.17	14,14	38	61.05	11.74	29	1.7%	-0.22 [-0.70, 0.27]	
Ariona (MCA) 2007	80.65	19.11	36	73.43	13	44	1.9%	0.45 [-0.00, 0.89]	
Chernyshev (LS. LSM, MCA) 2001	62.7	13.8	25	62.6	9.8	19	1.4%	0.01 (-0.59, 0.60)	
Chernyshev (LS, RSM, MCA) 2001	59	10.2	25	61.7	10.3	19	1.4%	-0.26 [-0.86, 0.34]	· · · · · · · · · · · · · · · · · · ·
Chernyshev (RS, LSM, MCA) 2001	57.7	13.3	25	62.6	9.8	19	1.4%	-0.40 [-1.01, 0.20]	
Chernyshev (RS, RSM, MCA) 2001	56.7	12.5	25	61.7	10.3	19	1.4%	-0.42 [-1.03, 0.18]	1
Choi (LS, MCA) 2017	64.2	11.2	28	62.5	10.47	28	1.6%	0.15 [-0.37, 0.68]	1. <u> </u>
Choi (RS, MCA) 2017	65.9	14.04	28	66.1	10.32	28	1.6%	-0.02 [-0.54, 0.51]	
Dora (MCA) 2003	64.9	9.9	20	59.1	9.9	11	1.0%	0.57 [-0.18, 1.32]	
El-Khawas (MCA) 2010	75.07	11.45	14	75.64	8.85	14	1.1%	-0.05 [-0.80, 0.69]	
Fiermonte (MCA) 1995	59.8	10.1	15	55.8	10.6	15	1.1%	0.38 [-0.35, 1.10]	
Fiermonte (MCA) 1999	66.79	10.01	12	58.6	9.39	21	1.1%	0.83 [0.09, 1.57]	
Haring (ACA) 1992	49	62.3	23	50	44.7	20	1.4%	-0.02 [-0.62, 0.58]	
Haring (MCA) 1992	59	57.5	23	60	53.7	20	1.4%	-0.02 [-0.62, 0.58]	
Heckmann (MCA) 1998	50.1	12.8	15	54.9	16.9	15	1.1%	-0.31 [-1.03, 0.41]	
Karacay Ozkalayci (ACA) 2018	47.88	7.38	30	48.71	8.5	25	1.6%	-0.10 [-0.63, 0.43]	
Karacay Ozkalayci (MCA) 2018	66.52	9.71	30	61.4	11.97	25	1.6%	0.47 [-0.07, 1.01]	
Perko (MCA) 2011	67.3	11.3	20	69	10.9	20	1.3%	-0.15 [-0.77, 0.47]	
Piccini (MCA) 1995	66.1	10.1	10	72.2	6.4	7	0.7%	-0.66 [-1.66, 0.34]	
Podgorac (MCA) 2018	57.1	10.98	70	55.85	11.93	30	2.0%	0.11 [-0.32, 0.54]	
Reinnard (MCA) 2012	57.5	1.5	17	60.7	8	30	1.4%	-0.40 [-0.99, 0.18]	
Silvestrini (DC, MCA) 1996	65.0	0.4	15	65 5	8.2	15	1.170	0.37 [-0.35, 1.09]	
Themaidee (MCA) 2002	65.3 EE A	10.6	15	64.6	22.0	15	1.170	-0.03 [-0.74, 0.09]	
Thomaides (S. MCA) 2003	56.3	16.7	15	54.6	22.0	15	1 1 96	0.09 [-0.63 0.90]	
Thomaides (7, MCA) 2003	55.8	16.7	15	54.6	22.0	15	1 1 96	0.06 [-0.03, 0.00]	
Thomsen (MCA) 1993	72	9	17	75	14	17	1 7%	-0.25[-0.92_0.43]	
Totaro (MCA) 1997	70.3	11	30	66 3	93	30	1 7%	0.39 [-0.12 0.90]	1
Subtotal (95% CI)	.0.3		651	50.5	0.0	585	37.3%	0.04 [-0.08, 0.15]	•
Heterogeneity: $Tau^2 = 0.01$; $Chi^2 = 20$	8.55, df =	27 (P =	0.38);	l² = 5%					
rest for overall ellect: Z = 0.60 (P = 0	.00)								
1.1.3 Mixed Abernathy (LS ACA) 1004	53.24	1314	192	44.05	124	20	2 206	0.71 10.36 1.071	
Abernathy (LS MCA) 1994	63.83	12 11	182	55 63	11 75	38	2.370	0.68 (0.32, 1.07)	
Abernathy (RS ACA) 1994	52 96	13.22	182	45.57	11 25	38	2.3 %	0.57 [0.52, 1.03]	2
Abernathy (RS, MCA) 1994	64 48	12.67	182	55.57	13.39	38	2.3%	0.69 [0.34 1.05]	
Anzola (LS, MCA) 1993	68	14	30	67	15	30	1.7%	0.07 [-0.44, 0.57]	
Anzola (RS, MCA) 1993	71	15	30	66	16	30	1.7%	0.32 [-0.19, 0.83]	
Fabjan (MCA) 2015	68	13	29	66	13	23	1.5%	0.15 [-0.40, 0.70]	
Kastrup (LS, ACA) 1998	43.1	10.6	20	47.8	9.1	30	1.5%	-0.48 [-1.05, 0.10]	
Kastrup (LS, MCA) 1998	53.5	13.1	20	58.9	14	30	1.5%	-0.39 [-0.96, 0.18]	
Kastrup (RS, ACA) 1998	42.7	10.1	20	49.3	8.5	30	1.4%	-0.71 [-1.29, -0.12]	
Kastrup (RS, MCA) 1998	53.5	12.8	20	59.6	12.9	30	1.5%	-0.47 [-1.04, 0.11]	
Rajan (LS, MCA) 2015	51.9	7.98	45	53.3	5.9	44	2.0%	-0.20 [-0.61, 0.22]	
Rajan (RS, MCA) 2015	51.4	8.12	45	51.7	6.91	44	2.0%	-0.04 [-0.45, 0.38]	
Reinhard (LS, MCA) 2007	54	9	16	50	9	70	1.5%	0.44 [-0.11, 0.99]	
Reinhard (RS, MCA) 2007	52	8	19	49	9	74	1.7%	0.34 [-0.17, 0.84]	
Valikovics (MCA) 1996	71	13	51	65	12	101	2.3%	0.48 [0.14, 0.82]	
Subtotal (95% CI)			1073			688	29.2%	0.17 [-0.05, 0.39]	•
Heterogeneity: Tau² = 0.15; Chi² = 5 Test for overall effect: Z = 1.54 (P = 0	r.67, df = 1.12)	15 (P <	0.000	J1); I≊ =	74%				
Total (95% CI)	a-104		2357			2053	100.0%	0 14 [0 05 0 22]	
Heteroneneity Tauz - 0.06. Chiz- 1	23.52 44	= 66 /P	< 0.000	11): 12-	47%	2000	100.070	0.14 [0.00, 0.20]	I
Test for overall effect: $7 = 3.05 / 0 = 0$	0.033, 013	- 00 (P	- 0.000	17,12	-17 70				-2 -1 0 1
and the second sec									

Figure 2. Forest plot of 67 quantitative comparisons of mean blood flow velocity in the anterior circulation in migraineurs versus controls taken from 30 studies. ACA: anterior cerebral artery; LS: left side of cerebral artery; MCA: middle cerebral artery; RS: right side of cerebral artery.

	Mig	raineur	S	C	ontrols			Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
1.2.1 Migraine with Aura									2
Altamura (PCA) 2018	437	11	39	47.3	12	16	24%	-0.31 (-0.90, 0.27)	
Altamura (PCA) 2019	46.8	12	56	48	13.8	53	31%	-0.09 [-0.47, 0.28]	
El-Khawas (PCA) 2010	38.18	5.07	13	34.9	5.78	14	1.8%	0 58 [-0 19, 1 36]	
Haring (PCA) 1992	32	33	17	36	44.7	20	2.2%	-0.10[-0.75, 0.55]	
Karacay Ozkalayci (BA) 2018	46.8	4.06	10	40.48	8.36	25	1.8%	0.83 (0.07, 1.59)	
Karacay Ozkalayci (PCA) 2018	25 27	2.89	10	24 06	2 77	25	1.9%	0 42 [-0 32 1 16]	
Karacay Ozkalayci (VA) 2018	38 47	8 76	10	34 33	6.93	25	1.9%	0.54 [-0.20, 1.29]	
Karadas (LS PCA) 2014	44 22	1.33	20	42.28	2.01	20	2.1%	1 12 [0 44 1 79]	
Karadas (RS PCA) 2014	42.56	2 55	20	40.99	1.6	20	2 2 %	0.72 [0.08, 1.36]	
Nedeltchev (LS, PCA) 2004	38	8.8	19	37.1	8.3	19	2 2%	0.10[-0.53, 0.74]	
Perko (PCA) 2011	31.1	11.2	20	39	6.2	20	2 2 96	-0.86 [-1.51 -0.20]	
Reinhard (PCA) 2012	40	5.8	17	42.2	7	35	2 4 %	-0.33 [-0.91 0.26]	
Totaro (BA) 1992	46.2	12.8	44	43.6	101	88	31%	0 23 -0 13 0 60	
Totaro (LS PCA) 1992	35.2	81	44	34 9	9.2	88	31%	0.03 [-0.33, 0.40]	
Totaro (RS PCA) 1992	37.1	8.2	44	36.1	9.2	88	3 1 96	0.11 [-0.25 0.47]	
Subtotal (95% CI)	51.1	0.2	383	50.1	0.2	556	35.4%	0.16 [-0.06, 0.38]	•
Heterogeneity: Tau ² = 0.10; Chi ²	= 33.69,	df = 14	(P = 0.	002); l²:	= 58%				
Test for overall effect: Z = 1.43 (F	P = 0.15)								
1.2.2 Migraine without Aura		0.00							
Akgun (PCA) 2015	35.41	6.98	38	36.52	12.64	29	2.7%	-0.11 [-0.60, 0.37]	
Chernyshev (LSM, BA) 2001	34.7	82	25	38.2	8	19	2.3%	-0.06 [-0.65, 0.54]	
Chernyshev (RSM, BA) 2001	39.5	5.6	25	38.2	8	19	2.3%	0.19 [-0.41, 0.79]	
Choi (BA) 2017	46.7	5.98	28	46.5	10.65	28	2.6%	0.02 [-0.50, 0.55]	
Choi (LS, PCA) 2017	36.5	6.65	28	37.4	6.58	28	2.6%	-0.13 [-0.66, 0.39]	
Choi (RS, PCA) 2017	36.8	6.36	28	38.8	7.14	28	2.5%	-0.29 [-0.82, 0.24]	
El-Khawas (PCA) 2010	43.21	6.73	14	34.9	5.78	14	1.7%	1.29 [0.46, 2.11]	
Haring (PCA) 1992	36	52.8	23	36	44.7	20	2.3%	0.00 [-0.60, 0.60]	
Karacay Ozkalayci (BA) 2018	43.96	9.48	30	40.48	8.36	25	2.5%	0.38 [-0.15, 0.92]	
Karacay Ozkalayci (PCA) 2018	25.45	3.04	30	24.06	2.77	25	2.5%	0.47 [-0.07, 1.01]	
Karacay Ozkalayci (VA) 2018	37.95	6.2	30	34.33	6.93	25	2.5%	0.55 [0.00, 1.09]	
Min (PCA) 2011	38.12	7.73	22	39.69	6.19	14	2.1%	-0.21 [-0.89, 0.46]	
Perko (PCA) 2011	40.3	7.2	20	29	6.2	20	1.9%	1.65 [0.92, 2.38]	
Reinhard (PCA) 2012	39	4.9	17	42.2	7	35	2.3%	-0.49 [-1.08, 0.10]	
Hotorogonoity Tour = 0.17: Chil	- 20.21	df = 12	/D = 0	00023-8	- 67%	JZS	JZ.370	0.20 [-0.07, 0.40]	
Test for overall effect: Z = 1.42 (F	P = 0.16	ui = 15	(r = 0.	0002),1	- 07 %				
1.2.3 Mixed									
Abernathy (BA) 1994	50.69	10.2	182	43 47	10 37	30	3 1 %	0.70.00.35.1.061	
Abernathy (LS PCA) 100/	45.66	12 96	192	36.59	12.49	20	3 1 94	0.70 (0.35, 1.00)	
Abernathy (LS, VA) 1004	49.00	10.57	192	43 37	11 52	30	3 204	0.50 (0.35, 1.00)	
Abernathy (EG, VA) 1334	51.52	11.52	102	45.60	10.62	20	3.270	0.50 [0.14, 0.65]	
Abernathy (RS VA) 100/	45.00	12.71	102	36.69	11 24	20	3 1 04	0.31 [0.10, 0.80]	
Eabian (PCA) 2015	40.99	12.71	20	30.30	7	30	2.170	0.75 [0.38, 1.11]	
Lastrun (IS PCA) 1000	80 9 9 6	70	29	40.1	0.2	23	2.070	-0.40[.0.07_0.40]	
Kastrup (EC, FCA) 1990	30.0	7.9	20	40.1	9.2	30	2.4%	-0.40[-0.97, 0.18]	
Daian (DA) 2015	34.7	7.3	20	90.0	3.0	14	2.470	-0.04 [-1.22, -0.00]	
Daian (LC DCA) 2015	116	6.04	40	45.1	9.01	44	2.370	-0.02 [*0.43, 0.40]	
Daian (DQ DCA) 2015	944.0	5.07	40	40.1	5.06	44	2.9%	-0.03 [-0.01, 0.33]	
Subtotal (95% CI)	30.0	0.87	1114	30.8	0.4	405	31.8%	0.23 [-0.02, 0.40]	•
Heterogeneity: $Tau^2 = 0.14$; Chi^2 Test for overall effect: $Z = 1.78$ (F	= 42.34, P = 0.07)	df = 10	(P < 0.	00001);	I ² = 769	%			
Total (95% CI)			1855			1200	100.0%	0 20 [0 05 0 34]	•
Heterogeneity: Tau ² = 0.13; Chi ²	= 121.00), df = 3	9 (P < (0.00001); I ² = 68	3%	100.0%	0.20 [0.03, 0.34]	
Test for overall effect: Z = 2.69 (F	P = 0.007)							-2 -1 0 1 2
Test for subgroup differences: C	;hi² = 0.1	7, df = 2	(P = 0	.92), I² =	0%				

Figure 3. Forest plot of 40 quantitative comparisons of mean blood flow velocity in the posterior circulation in migraineurs versus controls taken from 18 studies. BA: basilar artery; LS: left side of cerebral artery; PCA: posterior cerebral artery; RS: right side of cerebral artery; VA: vertebral artery.

The breath holding index (BHI) is a measure of CVR to the BHT, which is calculated by dividing the percentage increase of CBFV by the duration of the BHT. Some studies measured CVR by calculating a cerebral reactivity index (CRI) in which the change in CBFV from basal conditions is divided by the change in end tidal CO_2 . Other studies calculated CVR by calculating the percentage increase of CBFV during stimulation as follows: CVR (%) = (peak BFV during stimulation – resting CBFV)/resting CBFV) \times 100.

Twenty-six studies compared CVR to hypercapnia in the anterior circulation between migraineurs and controls with mixed results; 10 studies found migraineurs to have higher CVR to hypercapnia,^{16,21,30,32,35,50,51,54,58,59} five

	Mig	aineu	rs	Co	ntrols		3	Std. Mean Difference			Std. M	Aean Differen	се	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	Year		IV, R	andom, 95% (
2.1.1 Migraine with Aura														
Totaro (RS, PCA) 1992	0.86	0.22	44	0.8	0.12	88	7.4%	0.37 [0.01, 0.74]						
Totaro (LS, MCA) 1992	0.84	0.22	44	0.78	0.12	88	7.4%	0.37 [0.01, 0.74]	1992					
Totaro (RS, ACA) 1992	0.92	0.19	44	0.87	0.18	88	7.4%	0.27 [-0.09, 0.63]	1992			+		
Totaro (LS, ACA) 1992	0.89	0.2	44	0.85	0.16	88	7.4%	0.23 [-0.13, 0.59]	1992					
Fiermonte (MCA) 1995	0.87	0.18	15	0.98	0.2	15	3.0%	-0.56 [-1.29, 0.17]	1995	18				
Reinhard (MCA) 2012	0.62	0.14	17	0.65	0.09	35	4.3%	-0.27 [-0.85, 0.31]	2012		-			
Karacay Ozkalayci (ACA) 2018	0.89	0.14	10	1.02	0.18	25	2.9%	-0.75 [-1.50, 0.01]	2018	20				
Karacay Ozkalayci (MCA) 2018	1.08	0.24	10	1.03	0.18	25	3.0%	0.25 [-0.49, 0.98]	2018		0		_	
Podgorac (MCA) 2018	0.73	0.18	100	0.72	0.16	30	6.6%	0.06 [-0.35, 0.46]	2018					
Subtotal (95% CI)			328			482	49.5%	0.10 [-0.11, 0.31]				+		
Heterogeneity: Tau ² = 0.05; Chi ² = 14	.79, df=	8 (P=	= 0.06);	I ² = 469	6									
Test for overall effect: Z = 0.93 (P = 0.	35)													
2.1.2 Migraine without Aura														
Piccini (MCA) 1995	0.76	0.01	10	0.75	0.05	7	1.9%	0.29 [-0.68, 1.26]	1995		-	-	-	
Fiermonte (MCA) 1995	0.83	0.11	15	0.98	0.2	15	2.9%	-0.90 [-1.66, -0.15]	1995		-			
Chernyshev (LS, LSM, MCA) 2001	0.86	0.1	25	0.9	0.2	19	4.1%	-0.26 [-0.86, 0.34]	2001		-			
Chernyshev (LS, RSM, MCA) 2001	0.92	0.2	25	0.9	0.2	19	4.1%	0.10 [-0.50, 0.70]	2001		10			
Chernyshev (RS, LSM, MCA) 2001	0.88	0.1	25	0.9	0.2	19	4.1%	-0.13 [-0.73, 0.47]	2001					
Chernyshev (RS, RSM, MCA) 2001	0.97	0.2	25	0.9	0.2	19	4.1%	0.34 [-0.26, 0.94]	2001					
Dora (MCA) 2003	0.76	0.11	20	0.82	0.17	11	3.0%	-0.44 [-1.18, 0.31]	2003					
Arjona (MCA) 2007	0.77	0.13	36	0.8	0.12	44	6.1%	-0.24 [-0.68, 0.20]	2007					
Reinhard (MCA) 2012	0.64	0.1	17	0.65	0.09	35	4.3%	-0.11 [-0.69, 0.47]	2012		-			
Karacay Ozkalayci (ACA) 2018	1.02	0.21	30	1.02	0.18	25	4.8%	0.00 [-0.53, 0.53]	2018		-			
Karacay Ozkalayci (MCA) 2018	1.03	0.19	30	1.03	0.18	25	4.8%	0.00 [-0.53, 0.53]	2018		-			
Podgorac (MCA) 2018	0.68	0.12	70	0.72	0.16	30	6.2%	-0.30 [-0.73, 0.13]	2018					
Subtotal (95% CI)			328			268	50.5%	-0.14 [-0.31, 0.03]				•		
Heterogeneity: Tau ² = 0.00; Chi ² = 9.8	30, df = 1	11 (P =	= 0.55);	$ ^2 = 0\%$										
Test for overall effect: Z = 1.65 (P = 0.	10)													
T-1-1/054 0B			0.5.0			750	400.00	0.001.040.040						
l otal (95% Cl)	1242 1127	1212 322	656	1223 1223	12.02	750	100.0%	-0.02 [-0.16, 0.13]				-		
Heterogeneity: Tau ² = 0.04; Chi ² = 31	.36, df=	20 (P	= 0.05)); I [≈] = 36	96					-2	-1	0	1	2
Test for overall effect: Z = 0.22 (P = 0.	83)									100	0.005	-		-
Test for subgroup differences: Chi ² =	3.03, dt	f=1 (F	P = 0.08	$, ^2 = 6$	7.0%									

Figure 4. Forest plot of 21 quantitative comparisons of pulsatility index in the anterior circulation in migraineurs versus controls taken from nine studies. ACA: anterior cerebral artery; LS: left side of cerebral artery; LSM: left-sided migraineur; MCA: middle cerebral artery; RS: right side of cerebral artery; RSM, right-sided migraineur.

studies found migraineurs to have lower CVR to hypercapnia^{19,37,43,44,56} and nine studies found no difference in CVR to hypercapnia in the anterior circulation between migraineurs and controls.^{12,24,28,34,38,52,55,60} In Gonzalez-Quintanilla et al. and Choi et al., the comparison of CVR to hypercapnia between migraineurs and controls was unclear.^{18,53}

Figure 6 shows a forest plot of mean differences in CVR to hypercapnia in the anterior circulation between 32 migraine subgroups (n = 1166) and their respective controls (n = 937). Heterogeneity between comparisons was high ($I^2=85\%$) and there was no significant difference in CVR to hypercapnia (SMD = 0.11; 95%CI -0.13 to 0.35; P = 0.37) between migraineurs and controls.

Eleven studies compared CVR to hypercapnia in the posterior circulation between migraineurs and controls.^{12,18,19,21,24,35,50,51,53,56,57} Four studies found migraineurs to have higher CVR to hypercapnia in the posterior circulation^{21,35,50,51} and five studies found migraineurs to have lower CVR to hypercapnia in the posterior circulation.^{12,19,24,56,57}

Figure 7 shows a forest plot of mean differences in CVR to hypercapnia in the posterior circulation

between 19 migraine subgroups (n = 991) and their respective controls (n = 694). Once again, heterogeneity between comparisons was high $(I^2=89\%)$. The CVR to hypercapnia in the posterior circulation was significantly lower (SMD=-0.34; 95%CI -0.67 to -0.01; P = 0.04) in migraineurs.

Cerebrovascular responsiveness to hypocapnia

Hypocapnia is believed to measure the cerebral vasoconstrictor response.⁶¹ Eight studies compared CVR to hypocapnia in the anterior circulation in migraineurs to controls with varying results. All eight studies used stimulate hyperventilation hypocapto nia.^{26,34,37,40,43,59,62,63} Fiermonte et al.^{34,40} found migraineurs with aura to have a higher CRI than controls, while in migraineurs without aura it was similar to controls. Thomsen et al.⁶² similarly found migraineurs with aura to have a higher CRI to hypocapnia but found migraineurs without aura to have a lower CRI to hypocapnia than controls. El-Khawas et al.²⁶ found migraineurs to have lower CRI than controls. Anzola et al., Thomas et al., Totaro et al. and

	Mig	raineu	rs	Co	ontrols			Std. Mean Difference		Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	Year	IV, Random, 95% CI
2.2.1 Migraine with Aura							101.0			
Totaro (RS, PCA) 1992	0.94	0.23	44	0.89	0.23	88	11.9%	0.22 [-0.15, 0.58]		
Totaro (LS, PCA) 1992	0.94	0.29	44	0.89	0.2	88	11.9%	0.21 [-0.15, 0.58]	1992	+
Totaro (BA) 1992	0.83	0.18	44	0.82	0.13	88	11.9%	0.07 [-0.29, 0.43]	1992	
Reinhard (PCA) 2012	0.54	0.09	17	0.59	0.08	35	6.8%	-0.59 [-1.18, 0.00]	2012	
Karacay Ozkalayci (BA) 2018	1.26	0.38	10	1.03	0.28	25	4.7%	0.72 [-0.03, 1.48]	2018	
Karacay Ozkalayci (PCA) 2018	1.56	0.84	10	1.37	0.48	25	4.9%	0.31 [-0.43, 1.05]	2018	
Karacay Ozkalayci (VA) 2018 Subtotal (95% CI)	1.11	0.18	10 179	0.96	0.16	25 374	4.6% 56.7%	0.88 [0.12, 1.65]	2018	•
Heterogeneity: Tau ² = 0.07; Chi ²	= 12.33	df = 6	(P = 0)	05): ² =	51%			e 1 e		
Test for overall effect: Z = 1.42 (F	^o = 0.16)			//						
2.2.2 Migraine without Aura										
Chernyshev (RSM, BA) 2001	0.9	0.2	25	0.8	0.1	19	6.5%	0.60 [-0.01, 1.21]	2001	
Chernyshev (LSM, BA) 2001	0.9	0.2	25	0.8	0.1	19	6.5%	0.60 [-0.01, 1.21]	2001	
Reinhard (PCA) 2012	0.56	0.11	17	0.59	0.08	35	6.9%	-0.33 [-0.91, 0.26]	2012	
Karacay Ozkalayci (PCA) 2018	1.61	0.74	30	1.37	0.48	25	7.7%	0.37 [-0.16, 0.91]	2018	
Karacay Ozkalayci (VA) 2018	1.01	0.2	30	0.96	0.16	25	7.8%	0.27 [-0.26, 0.80]	2018	
Karacay Ozkalayci (BA) 2018 Subtotal (95% CI)	1.12	0.4	30 157	1.03	0.28	25 148	7.8% 43.3%	0.25 [-0.28, 0.79] 0.29 [0.03, 0.55]	2018	•
Heterogeneity: Tau ² = 0.02; Chi ² Test for overall effect: Z = 2.16 (F	e = 6.33, (= 0.03)	df= 5 (P = 0.2	8); I² = :	21%					
Total (95% CI)			336			522	100.0%	0.23 [0.05, 0.42]		•
Heterogeneity: $Tau^2 = 0.04$; Chi ² Test for overall effect: $7 = 2.46$ /6	= 19.21	, df = 1	2 (P =)	0.08); I²	= 38%					
Test for subgroup differences: C	= 0.01) hi ² = 0.2	0. df=	1 (P =	0.66), P	² = 0%					

Figure 5. Forest plot of 13 quantitative comparisons of pulsatility index in the posterior circulation in migraineurs versus controls taken from four studies. BA: basilar artery; LSM; left-sided migraineur; MCA: middle cerebral artery; PCA: posterior cerebral artery; RSM: right-sided migraineur; VA: vertebral artery.

Zwetsloot et al. all found migraineurs and controls to have similar CVR to hypocapnia.^{37,43,59,63}

Figure 8 shows a forest plot of mean differences in CVR to hypocapnia in the anterior circulation between nine migraine subgroups (n = 157) and their respective controls (n = 195). Heterogeneity between comparisons was high ($I^2=74\%$) and there was no significant difference in CVR to hypocapnia (SMD=0.01; 95%CI -0.43 to 0.46; P = 0.95) between migraineurs and controls.

Neurovascular coupling

During neurovascular coupling, the MBFV in the cerebral artery or brain region of interest is measured while participants are shown a stimulus that provokes increases in neural activity, such as a cognitive task (e.g. Stroop task) or photic stimulation task (e.g. checkerboard pattern reversal). Changes in MBFV relative to basal conditions is used to calculate neurovascular coupling.²⁵

Eight studies compared neurovascular coupling during photic stimulation in the posterior circulation between migraineurs and controls.^{20,25,29,47,64–68} Studies found migraineurs to have higher neurovascular coupling during photic stimulation compared to controls: Thie et al.⁶⁶ in migraineurs; Nedeltchev et al.²⁹ in migraineurs with aura; Zaletel et al.^{47,68} in migraineurs and migraineurs with aura; Wolf et al.⁶⁷ in migraineurs with aura. Min et al.²⁵ was the only study to find that neurovascular coupling was similar participants with migraine and controls. Both studies by Backer et al.^{64,65} found migraineurs to have a higher initial increase of CBFV than controls following the onset of photic stimulation.

Figure 9 shows a forest plot of mean differences in neurovascular coupling during photic stimulation in the posterior circulation between six migraine subgroups (n=220) and their respective controls (n=152). Heterogeneity between comparisons was moderate ($I^2 = 59\%$) and there was no significant difference in the neurovascular coupling (SMD=0.20; 95%CI -0.15 to 0.55) between migraineurs and controls (P = 0.26).

Cerebral autoregulation

During cerebral autoregulation, cerebral blood flow is maintained constant despite fluctuations of cerebral perfusion pressure. Six studies compared cerebral autoregulation in the anterior circulation of migraineurs to controls.^{23,27,36,52,69,70} Different metrics and indexes were used to assess cerebral autoregulation, which included gain, phase, Mx and Dx. Gain

	Mig	raineur	S	Co	ontrols			Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
3.1.1 Migraine with Aura									
Altamura (MCA) 2018	1.9	0.7	39	1.5	0.4	16	3.1%	0.63 [0.03, 1.22]	
Altamura (MCA) 2019	1.84	0.47	56	1.53	0.47	53	3.5%	0.65 [0.27, 1.04]	
Gollion (MCA) 2018	36.3	0.61	22	37.1	0.99	22	3.0%	-0.96 [-1.58, -0.33]	· · · · · · · · · · · · · · · · · · ·
Karadas (LS. MCA) 2014	1.53	0.1	20	1.38	0.12	20	2.9%	1.33 [0.64, 2.02]	
Karadas (RS MCA) 2014	1 49	0.18	20	1.36	0.11	20	3.0%	0.85 (0.20, 1.50)	· · · · · · · · · · · · · · · · · · ·
Perko (MCA) 2011	14	82	20	16.4	65	20	3.0%	-0.32[-0.94]0.31]	
Podgorac (MCA) 2018	1 69	0.27	100	12	0.27	30	3 396	1 80 [1 34 2 27]	
Rivestrini (LS MCA) 1996	1 1 1	0.21	15	1 25	0.21	15	2.9%	-0.53[-1.26, 0.20]	
Silvestrini (MCA) 2004	1.41	0.1	15	1.41	0.1	15	2.0%	0.00 [.0.72 0.72]	
Cilvestrini (DC MCA) 1006	1.41	0.1	15	1.41	0.1	15	2.0 %	0.00[0.72, 0.72]	
Entore (MCA) 1007	1.57	1.1	20	1 74	0.0	20	2.0%	0.24 [-0.35, 0.46]	
(orpiori (MCR) 2000	1.57	16	10	1.74	47	30	3.370	-0.17 [-0.00, 0.33]	
Subtotal (95% CI)	60	10	368	47	17	277	36.5%	0.33 [-0.15, 0.81]	-
Heterogeneity: Tau ² = 0.61; Chi ² = 85.52	. df = 11	(P < 0	.00001); $ ^2 = 8$	7%				
Fest for overall effect: Z = 1.36 (P = 0.17)								
3.1.2 Migraine without Aura									
koun (MCA) 2015	1.22	0.47	31	1.45	0.57	29	3.2%	-0.44 [-0.95, 0.08]	
Ariona (MCA) 2007	1.6	0.72	36	1.56	0.65	44	3 4 96	0.06 [-0.38 0.50]	
Choi (I S. MCA) 2017	1.1	0.34	28	1.00	0.24	28	3.7%	-0.34 (-0.96, 0.10)	
2017	1.1	0.52	20	1.2	0.24	20	2 206	0.00[0.52 0.52]	
oro (MCA) 2002	1.5	0.32	20	1.5	0.35	20	3.2%	1 24 [0 42 2 05]	· · · · · · · · · · · · · · · · · · ·
Porte (MCA) 2003	14.5	0.5	20	1.20	0.30	20	2.7 %	0.29 (0.00, 0.24)	
Perko (MCA) 2011	14.0	0.0	20	10.4	0.0	20	3.070	-0.20 [-0.90, 0.34]	
Pulgorac (MCA) 2018	1.41	0.30	10	1.2	0.27	30	3.470	0.02 [0.16, 1.00]	
Silvestrini (LS, MCA) 1996	1.18	0.3	15	1.25	0.3	15	2.8%	-0.23 [-0.95, 0.49]	10 I
Silvestrini (MCA) 2004	1.27	0.4	15	1.4	0.5	15	2.8%	-0.28 [-1.00, 0.44]	
Silvestrini (RS, MCA) 1996	1.42	0.1	15	1.41	0.1	15	2.9%	0.10[-0.62, 0.81]	
otaro (MCA) 1997 Subtotal (95% CI)	1.09	0.5	30	1.74	0.8	265	3.2%	-0.96 [-1.50, -0.43] -0.06 [-0.39, 0.26]	_ _
Heterogeneity: Tau ² = 0.21; Chi ² = 34.83), df = 10	(P = 0	.0001)	; I ² = 71	%				
Test for overall effect: Z = 0.39 (P = 0.70))								
3.1.3 Mixed									
onzalez-Quintanilla (CM, MCA) 2016	0.63	0.48	35	1.43	0.67	41	3.3%	-1.34 [-1.84, -0.84]	
onzalez-Quintanilla (EM, MCA) 2016	1.04	0.48	37	1.43	0.67	41	3.3%	-0.66 [-1.11, -0.20]	
(astrup (LS, ACA) 1998	5.25	0.8	20	4.18	1.5	30	3.1%	0.83 [0.24, 1.42]	
(astrup (LS, MCA) 1998	4.85	1.1	20	4.32	1.2	30	3.1%	0.45 [-0.12, 1.02]	
(astrup (RS, ACA) 1998	5.28	0.9	20	4.37	1.5	30	3.1%	0.69 [0.11, 1.27]	
(astrup (RS, MCA) 1998	5.61	1.4	20	4.42	1.3	30	3.1%	0.87 [0.28, 1.47]	
ee (MCA) 2019	1.11	0.33	248	1.19	0.31	105	3,7%	-0.25 [-0.48, -0.02]	
Raian (LS. MCA) 2015	1.08	0.47	45	1.15	0.4	44	3.4%	-0.16 [-0.58, 0.26]	
Raian (RS_MCA) 2015	1.22	0.6	45	1 23	0.6	44	3 4 %	-0.02[-0.43_0.40]	
Subtotal (95% CI)	1.22	0.0	490	1.20	0.0	395	29.6%	0.02 [-0.39, 0.44]	+
Heterogeneity: Tau ² = 0.34; Chi ² = 61.46	i. df = 8 i	P<00	00001)	² = 87	%				
Test for overall effect: Z = 0.10 (P = 0.92)		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,						
fotal (95% CI)			1166			937	100.0%	0.11 [-0.13, 0.35]	•
Heterogeneity: $Tau^2 = 0.40$; $Chi^2 = 200.6$	0 df= 3	1 (P <	0.0000	11): IF = 1	85%				
Test for overall effect 7 = 0.90, OH = 203.0)	. 4 .	0.0000		00.0				-2 -1 0 1 2
Cast for subgroup differences: $Chi^2 = 1.00$	23 df-	2 (P - 0	1.40) 19	- 0%					
source subgroup unierences. Off = 1,	00, ui – 1	- (r - t		- 0.0					

Figure 6. Forest plot of 32 quantitative comparisons of cerebrovascular responsiveness to hypercapnia in the anterior circulation in migraineurs versus controls taken from 18 studies. ACA: anterior cerebral artery; CM: chronic migraineurs; EM: episodic migraineur; LS: left side of cerebral artery; MCA; middle cerebral artery; RS: right side of cerebral artery.

measures the amount of mean arterial blood pressure (MABP) variation that is transferred onto MBFV; a lower gain is associated with a more efficient cerebral autoregulation. Phase reflects the time delay between MABP and MBFV signals; a positive phase value indicates that cerebral autoregulation is intact, whereas a negative phase indicates impaired cerebral autoregulation. Mx is used to measure the correlation between MABP and MBFV; cerebral autoregulation is deemed as optimal when values of Mx are close to 0, whereas Mx values close to 1 indicate impaired cerebral autoregulation. Dx is used to measure the degree of correlation between diastolic MABP and diastolic MBFV; the higher the Dx, the poorer the cerebral autoregulation. Most studies found no difference in phase, gain, Dx or Mx between migraineurs and controls.^{27,52} However, Wallasch et al.⁶⁹ found migraineurs to have a lower gain than controls.

Wallasch et al. used the Valsalva manoeuvre, a breathing exercise that results in a rapid increase of arterial blood pressure, to assess cerebral autoregulation between migraineurs and controls. Wallasch et al.⁷⁰ found migraineurs to have a higher cerebral auto-regulatory response to the Valsalva manoeuvre, compared to controls, indicating poorer cerebral autoregulation.

	Migr	aineu	rs	Co	Controls			Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
3.2.1 Migraine with Aura									
Altamura (PCA) 2018	1.8	0.4	39	1.6	0.4	16	5.2%	0.49 [-0.10, 1.08]	
Altamura (PCA) 2019	1.87	0.65	56	1.47	0.44	53	5.7%	0.71 [0.32, 1.10]	
Karadas (LS, PCA) 2014	1.5	0.11	20	1.42	0.08	20	5.0%	0.82 [0.17, 1.46]	
Karadas (RS, PCA) 2014	1.54	0.15	20	1.41	0.13	20	5.0%	0.91 [0.25, 1.56]	
Perko (PCA) 2011	14.3	8.3	20	21.3	8.2	20	5.0%	-0.83 [-1.48, -0.18]	
Silvestrini (BA) 2004 Subtotal (95% CI)	0.83	0.3	15 170	1.39	0.1	15 144	4.0% 29.8%	-2.44 [-3.41, -1.46] 0.00 [-0.80, 0.81]	
Heterogeneity: Tau ² = 0.90;	$Chi^2 = 5$	2.44.	df = 5 (1	< 0.00	001); [= 90%	6		
Test for overall effect: Z = 0.	.01 (P =	1.00)							
3.2.2 Migraine without Aur	a								
Akgun (PCA) 2015	1.24	0.53	31	1.37	0.51	29	5.4%	-0.25 [-0.75, 0.26]	
Choi (BA) 2017	1	0.38	28	1.3	0.43	28	5.3%	-0.73 [-1.27, -0.19]	
Choi (LS, PCA) 2017	1.1	0.34	28	1.3	0.49	28	5.3%	-0.47 [-1.00, 0.06]	
Choi (RS, PCA) 2017	1	0.42	28	1.1	0.31	28	5.3%	-0.27 [-0.79, 0.26]	
Perko (PCA) 2011	14.4	7.6	20	21.3	8.2	20	5.0%	-0.86 [-1.51, -0.20]	
Silvestrini (BA) 2004	1.42	0.1	15	1.39	0.1	15	4.8%	0.29 [-0.43, 1.01]	
Subtotal (95% CI)			150			148	31.1%	-0.40 [-0.68, -0.11]	•
Heterogeneity: Tau ² = 0.04;	Chi ² = 7	.50, d	f= 5 (P	= 0.19);	I ² = 33	3%			
Test for overall effect: $Z = 2$.	.73 (P = 1	0.006)							
3.2.3 Mixed									
Kastrup (LS, PCA) 1998	5.05	1.4	20	4,94	1.8	30	5.2%	0.07 [-0.50, 0.63]	
Kastrup (RS, PCA) 1998	5.72	1.7	20	4.43	1.7	30	5.2%	0.75 [0.16, 1.33]	
Lee (BA) 2019	0.94	0.4	248	1.09	0.36	105	6.0%	-0.39 [-0.62, -0.16]	
Lee (PCA) 2019	1.13	0.4	248	1.29	0.4	105	6.0%	-0.40 [-0.63, -0.17]	
Rajan (BA) 2015	0.61	0.4	45	1.12	0.27	44	5.5%	-1.48 [-1.95, -1.01]	
Rajan (LS, PCA) 2015	0.8	0.47	45	1.43	0.4	44	5.5%	-1.43 [-1.90, -0.96]	
Rajan (RS, PCA) 2015	0.77	0.47	45	1.31	0.4	44	5.5%	-1.23 [-1.68, -0.77]	·
Subtotal (95% CI)			671			402	39.0%	-0.60 [-1.07, -0.14]	•
Heterogeneity: Tau ² = 0.34;	Chi ² = 6	3.97,	df = 6 (l	° < 0.00	001); I	² = 91%	6		
Test for overall effect: Z = 2.	.53 (P =	0.01)							
Total (95% CI)			991			694	100.0%	-0.34 [-0.67, -0.01]	◆
Heterogeneity: Tau ² = 0.45;	Chi ² = 1	63.25	, df = 11	3 (P < 0.	00001); I ^z = 8	9%		
Test for overall effect: Z = 2.	.04 (P =	0.04)							-2 -1 0 1 2
Test for subgroup differenc	es: Chi²	= 1.65	i, df = 2	(P = 0.4)	14), I ² =	:0%			

Figure 7. Forest plot of 19 quantitative comparisons of cerebrovascular responsiveness to hypercapnia in the posterior circulation in migraineurs versus controls taken from 10 studies. BA: basilar artery; LS: left side of cerebral artery; PCA: posterior cerebral artery; RS: right side of cerebral artery.

The meta-analyses revealed no significant difference in phase (SMD = 0.13; 95%CI -0.11 to 0.36; P = 0.29), gain (SMD=-0.21; 95%CI -0.43 to 0.01; P = 0.06), Mx (SMD=0.05; 95%CI -0.34 to 0.44; P = 0.80) and Dx (SMD=0.29; 95%CI -0.08 to 0.66; P = 0.12) between migraineurs and controls in the anterior circulation (Supplemental Figures 1 to 4).

Reinhard et al. was the only study to compare the cerebral autoregulation of migraineurs to controls in the posterior circulation; no difference in phase, gain, Dx or Mx between migraineurs and controls was found.²³

Cerebrovascular function assessed using fMRI

Resting cerebral blood flow

Eight studies used fMRI to assess the resting CBF of migraineurs to compare to controls.^{71–78}

Hodkinson et al.⁷² compared CBF in the primary somatosensory cortex of migraineurs to controls. They found migraineurs without aura to have higher resting CBF in the primary somatosensory cortex when compared to controls.

Datta et al.⁷¹ compared CBF in the primary visual cortex between migraineurs and controls and found no difference in CBF. Additionally, Ances et al.⁷⁷ found no difference in resting CBF in the occipital lobe when menstrual migraineurs were compared to controls.

Zhang et al.⁷⁵ compared the grey, global and white matter CBF of migraineurs to controls and found no difference between the two groups. Similarly, Chen et al.⁷⁸ found there to be no difference in grey matter CBF between migraineurs and controls.

Neurovascular coupling

Hu et al.⁷³ used fMRI to assess cerebrovascular function; they found migraineurs to have lower

	Migraineurs			Controls				Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
4.1.1 Migraine with Aura									
El-Khawas (MCA) 2010	20.25	10.55	13	34.9	5.78	14	9.4%	-1.69 [-2.59, -0.79]	
Fiermonte (MCA) 1995	0.02	0.01	15	0.02	0.01	15	11.0%	0.00 [-0.72, 0.72]	
Thomsen (MCA) 1995	0.31	0.23	8	0.15	0.11	30	10.0%	1.11 [0.28, 1.93]	
Totaro (MCA) 1997	2.41	1.1	30	2.85	1.7	30	12.7%	-0.30 [-0.81, 0.21]	
Subtotal (95% CI)			66			89	43.2%	-0.21 [-1.15, 0.73]	
Heterogeneity: Tau ² = 0.78	3; Chi =	20.68,	df = 3 (P = 0.00	001); l ^z	= 85%			
Test for overall effect: Z = 0	0.44 (P :	= 0.66)							
4.1.2 Migraine without Au	Ira								
El-Khawas (MCA) 2010	30.68	8.74	14	34.9	5.78	14	10.6%	-0.55 [-1.31, 0.20]	
Fiermonte (MCA) 1995	0.03	0.01	15	0.02	0.01	15	10.6%	0.97 [0.21, 1.74]	
Thomsen (MCA) 1995	0.19	0.14	12	0.15	0.11	30	11.3%	0.33 [-0.34, 1.00]	
Totaro (MCA) 1997	2.92	1.9	30	2.85	1.7	30	12.8%	0.04 [-0.47, 0.54]	
Zwetsloot (MCA) 1991	0.21	0.08	20	0.2	0.08	17	11.6%	0.12 [-0.52, 0.77]	
Subtotal (95% CI)			91			106	56.8%	0.17 [-0.25, 0.59]	•
Heterogeneity: Tau ² = 0.12	2; Chi ² =	8.25, d	f=4 (P	= 0.08)	; 2 = 5;	2%			· · ·
Test for overall effect: Z = 0	0.79 (P :	= 0.43)							
Total (95% CI)			157			195	100.0%	0.01 [-0.43, 0.46]	+
Heterogeneity: Tau ² = 0.34	1; Chi ² =	31.24,	df = 8 (P = 0.00	001); l ^z	= 74%		-	
Test for overall effect: Z = 0	0.06 (P :	= 0.95)							-2 -1 0 1 2
Test for subgroup differen	ces: Ch	i ² = 0.53	2, df = 1	(P = 0.	47), I2:	= 0%			

Figure 8. Forest plot of nine quantitative comparisons of cerebrovascular responsiveness to hypocapnia in the anterior circulation in migraineurs versus controls taken from five studies. MCA: middle cerebral artery.



Figure 9. Forest plot of six quantitative comparisons of neurovascular coupling during photic stimulation in the posterior circulation in migraineurs versus controls taken from five studies. BA: basilar artery; HIS: higher side; LOS: lower side; LS: left side of cerebral artery; PCA: posterior cerebral artery.

neurovascular coupling during cognitive stimulation (Stroop task) than controls in the left inferior parietal gyrus, left superior marginal gyrus and left angular gyrus but higher neurovascular coupling in the right superior occipital gyrus and right superior parietal gyrus.

Cerebrovascular function assessed by NIRS

Three studies were identified from the systematic search that used NIRS to assess the cerebrovascular function of migraineurs to compare to controls.

Cerebrovascular responsiveness to hypercapnia

Akin et al. and Vernieri et al. assessed CVR to hypercapnia in the frontal cortex/frontotemporal region with conflicting findings; Akin et al. found migraineurs to have lower CVR to hypercapnia, whereas Vernieri et al. found migraineurs to have higher CVR to hypercapnia.^{48,79}

Neurovascular coupling

Schytz et al.⁸⁰ used NIRS to assess neurovascular coupling during the Stroop task in the frontal cortex and found no difference between migraineurs without aura and controls.

Cerebrovascular function assessed by SPECT

Six studies used SPECT to assess the resting CBF of migraineurs and controls.49,81-85 Cheng et al., De Benedittis et al. and Mirza et al. compared the resting CBF in the frontal, occipital, parietal and temporal lobes of migraineurs to controls.^{49,84,85} De Benedittis et al. found no difference in resting CBF between migraineurs and controls, whereas Cheng et al. and Mirza et al. both found migraineurs to have lower CBF in the frontal and occipital lobes.49,84,85 Cheng et al. additionally found migraineurs to have lower CBF in the parietal and occipital lobes.⁸⁴ Meyer et al. compared the CBF of grey, white and global matter of migraineurs to controls and found there to be no difference in CBF between the two groups.⁸¹ Facco et al. and Levine et al. compared CBF in the posterior territory of migraineurs to controls and both found migraineurs to have lower posterior CBF than controls.^{82,83}

Subgroup analysis

For all outcomes, subgroup analyses revealed no significant difference between migraine subgroups (migraine with aura, migraine without aura and mixed; chronic migraineurs and episodic migraineurs) (Supplemental Table 1(a) and (b), Supplemental Figures 5 to 8). However, the migraine with aura subgroup was the only subgroup where MBFV in the anterior circulation was found to be significantly higher than controls (SMD = 0.19; 95%CI 0.06 to 0.32, P = 0.005). Additionally, the PI in the posterior circulation was found to be significantly higher than controls in the migraine without aura subgroup only (SMD = 0.29; 95% CI 0.03 to 0.55, P = 0.03); this finding was not significant in the migraine with aura subgroup (SMD = 0.20; 95%CI -0.08 to 0.48, P = 0.16). The subgroup analyses also revealed that CVR to hypercapnia in the posterior circulation was significantly lower in migraineurs than controls for all subgroups

(migraine without aura, mixed and episodic migraineurs) except the chronic migraine and migraine with aura subgroups.

Risk of bias

All studies included in the meta-analyses were of moderate or high methodological quality; scores for all studies were between 5 and 9 points on the NOS (see Table 1).

Publication bias

There was no evidence of publication bias upon visual examination of funnel plots for the meta-analyses for MBFV and CVR to hypercapnia in the anterior and posterior circulations (see Supplemental Figure 9). However, the P value for the Egger's regression test for the meta-analysis for PI in the anterior circulation suggested that there was publication bias (Supplemental Table 2). Duval and Tweedie's trimand-fill estimated an additional six studies to the right of the mean and a revised point estimate of 0.22 (-0.04to 0.24) for PI in the anterior circulation.

Discussion

Summary of findings

Our systematic search identified 70 articles that compared the cerebrovascular function of migraineurs with that of controls. This review and meta-analysis builds on the findings of a recent narrative review by Ornello et al. where the cerebrovascular function of migraineurs, as measured by TCD ultrasound and NIRS, was compared to controls. To the best of our knowledge, this is the first meta-analysis to investigate whethcontrols have er migraineurs and differing cerebrovascular function. Similar to the review by Ornello et al., the qualitative findings of fMRI, NIRS, SPECT and TCD ultrasound studies included in this present review were inconsistent and did not provide a clear indication as to whether the cerebrovascular function of migraineurs differed to controls.13 However, our meta-analyses of TCD ultrasound studies were able to provide a better indication as to whether migraineurs have differing cerebrovascular function to controls as meta-analyses revealed migraineurs to have higher resting MBFV, higher PI and lower CVR to hypercapnia. Our findings of higher resting MBFV in migraineurs were evident in both the anterior and posterior cerebral circulations, whereas our findings of higher PI and lower CVR to hypercapnia were restricted to the posterior circulation. The revised point estimate after the trim-and-fill method revealed no significant difference for PI in the anterior circulation between migraineurs and controls. Subgroup analysis revealed higher resting MBFV in the anterior circulation to be more evident in migraineurs with aura, whereas higher PI and lower CVR to hypercapnia in the posterior circulation were found to be more evident in migraineurs without aura. Additionally, episodic migraineurs were found to have significantly lower CVR to hypercapnia in the posterior circulation.

Cerebrovascular responsiveness to hypercapnia

CVR assesses the ability of cerebral blood vessels to dilate and constrict in response to metabolic stimuli (i.e. arterial CO_2). High concentrations of arterial CO₂ (hypercapnia) stimulate increased production of nitric oxide (a potent vasodilator) from endothelial cells, whereas low arterial CO₂ concentrations (hypocapnia) result in decreased concentrations of endothelial-derived nitric oxide.86,87 Therefore, CVR to hypercapnia assesses endothelial dysfunction by measuring the ability of cerebral endothelial cells to produce nitric oxide to facilitate cerebral vasodilation. Our finding of lower CVR to hypercapnia in migraineurs reflects a lower cerebrovascular dilator capacity in the posterior circulation of migraineurs. Lower cerebral vasodilator capacity has previously been associated with an increased risk of cerebrovascular disease (i.e. haemorrhagic and ischaemic stroke). King et al.88 found lower CVR to hypercapnia in patients with asymptomatic and symptomatic carotid artery stenosis to be associated with a higher risk of both ischaemic and haemorrhagic stroke. Interestingly, migraine has also been associated with an increased risk of cerebrovascular disease.^{89–92} A meta-analysis by Mahmoud et al.⁹⁰ revealed migraineurs to have an increased risk of ischaemic stroke, haemorrhagic stroke and myocardial infarction compared to controls. Additionally, meta-analyses by Sacco et al.⁸⁹ and Spector et al.⁶ have also found migraineurs to have an increased risk of haemorrhagic stroke and ischaemic stroke respectively when compared to controls. Therefore, that raises a question of whether the association between migraine and stroke is partially attributable to altered cerebrovascular function as represented by lower cerebral vasodilator capacity than controls. However, previous studies have predominantly found migraineurs with aura to have a higher risk of cerebrovascular disease but have been unable to confirm this association in migraineurs without aura. This is particularly interesting as our subgroup analysis revealed a significant difference in lower CVR to hypercapnia in the posterior circulation of migraineurs without aura but not migraineurs with aura. However, findings in the migraine with aura subgroup may have been limited by the high statistical heterogeneity.

It is plausible that our finding of higher cerebral arterial stiffness, as represented by higher PI in migraineurs reflects pathological changes that may underlie the lower CVR to hypercapnia in the posterior cerebral arteries. Once again, our finding of higher PI in the posterior circulation of migraineurs was significantly higher in the migraineurs without aura subgroup but not the migraineurs with aura subgroup; high statistical heterogeneity in the migraineurs with aura subgroup may have limited the findings. Additionally, our finding of higher resting MBFV in migraineurs may also be associated with the lower CVR to hypercapnia; the higher resting MBFV may dampen the ability of cerebral blood vessels to dilate which may make the brain more susceptible to ischemia in times where an increase of cerebral blood flow is urgently required.⁹³

Cerebral autoregulation

Cerebral autoregulation describes the process whereby cerebral blood flow is maintained constant over a wide range of cerebral perfusion pressure, often from 50 to 150 mmHg in healthy adults.⁸⁶ Cerebral autoregulation may be compromised in conditions such as postural hypotension or essential hypertension, where cerebral perfusion pressures exceed the limits of cerebral autoregulation, thereby increasing an individual's risk of ischemia or hyperemia.^{86,87} Thus, an impairment of cerebral autoregulation in migraineurs may partially explain their increased risk of ischemic stroke.

This review identified only six studies that compared cerebral autoregulation between migraineurs and controls; qualitative and quantitative analyses of autoregulation in the anterior and posterior circulations revealed no clear difference between migraineurs and controls. Interestingly, Reinhard et al. reported that migraineurs with aura have poorer autoregulation in the cerebellar circulation than controls.²³ Further studies are needed to confirm whether autoregulation, particularly in posterior and cerebellar circulations, is compromised in migraineurs and whether this is associated with an increased risk of stroke.

Neurovascular coupling

Neurovascular coupling describes a process wherein cerebral blood flow is increased in local brain regions to meet the demands of higher neuronal activity.⁸⁷ Therefore, impaired or abnormal neurovascular coupling may result in inadequate blood supply to areas of the brain that need it. Qualitative findings in our review indicate that neurovascular coupling during photic stimuli is greater in migraineurs than controls, in agreement with the narrative review by Ornello et al.,¹³ yet our meta-analyses reveal no difference in

neurovascular coupling during photic stimuli between migraineurs and controls. However, statistical heterogeneity was high and due to the small number of studies included in the meta-analysis of neurovascular coupling, we were unable to test for risk of publication bias with Egger's regression. Nonetheless, the lower CVR to hypercapnia and higher PI in the posterior circulation of migraineurs suggest that their neurovascular coupling may also differ from controls. If future studies confirm that migraine is associated with impaired neurovascular coupling, interventions that improve neurovascular coupling may help to improve migraine symptomatology.

Localisation of altered cerebrovascular function to the posterior circulation

The localisation of higher resting MBFV, higher PI and lower CVR to hypercapnia in the posterior circulation of migraineurs suggests that the posterior circulation is more susceptible to variations in cerebrovascular function than the anterior circulation. This increased susceptibility to altered cerebrovascular function may be attributable to differences in the anatomical structure of the circle of Willis in migraineurs. Cucchiara et al.⁹⁴ and Bugnicourt et al.95 found that migraineurs were more likely to have an incomplete circle of Willis compared to controls, particularly in the posterior circulation.⁹⁵ Additionally, Cucchiara et al.⁹⁴ reported that anatomical variants of the circle of Willis in the posterior circulation were associated with more hemispheric CBF asymmetries than the anterior circulation. Therefore, it is plausible that differences in the anatomical structure of cerebral arteries in the posterior circulation may affect cerebral haemodynamics and consequently affect factors such as shear stress in a way that contributes to endothelial dysfunction; both abnormally high and low shear stress has been associated with endothelial dysfunction.⁹⁶ Further studies are needed to confirm this association and to investigate whether hemispheric asymmetries of CBF in migraineurs with an incomplete circle of Willis are associated with unilateral migraine.

Proposed migraine pathophysiology and altered cerebrovascular function

It has been hypothesised that repeated episodes of migraine may lead to altered cerebrovascular function through repeated exposure to neurogenic inflammation, plasma protein extravasation and the release of vasoactive neuropeptides during migraine; therefore, abnormalities of cerebrovascular function may be expected to be more evident in chronic migraineurs than episodic migraineurs.^{12,24} However, our findings

of significantly lower CVR to hypercapnia in the posterior circulation in episodic migraineurs but chronic migraineurs do not support this theory. Nevertheless, the number of comparisons and studies included in the separate meta-analyses for chronic and episodic migraineurs was small: there were only three comparisons from one study by Choi et al.¹⁸ in the subgroup analysis of episodic migraineurs. Further studies are needed to determine whether episodic migraineurs and chronic migraineurs differ in their cerebrovascular function. Additionally, some evidence suggests that altered cerebral vasodilator capacity may be involved in the pathophysiology of migraine through the initiation of cortical spreading depression (CSD) and subsequent pain pathways.⁹⁷ CSD is a process that is believed to be responsible for producing aura symptoms in some migraineurs. During CSD, neurones spontaneously depolarise, resulting in excitation of neuronal and glial activity that is shortly followed by suppression of neuronal and glial activity.²⁴ Interestingly, the depolarisation of neurons during CSD originates in posterior parts of the brain and spreads anteriorly; which may suggest that alterations in the cerebrovascular function of posterior brain regions may be involved in initiating CSD. Additionally, animal studies have shown that CSD can lead to neurogenic inflammation and plasma protein extravasation of cerebral blood vessels,⁹⁸ possibly though activation of the TVS. Therefore, alterations of cerebrovascular function may trigger migraine via CSD, and CSD may in turn further alter cerebrovascular function via neurogenic inflammation. Future studies are needed to further investigate the potential relationships between cerebrovascular function, CSD, activation of the TVS and neurogenic inflammation.

Combined oral contraceptives and cerebrovascular function

The use of combined oral contraceptives (COCs) (i.e. contraceptives that contain both oestrogen and progesterone) in migraineurs may be associated with an increased risk of ischaemic stroke.99,100 Whilst endogenous oestrogens may lower blood pressure, exogenous oral oestrogens tend to raise blood pressure in women, albeit only marginally.¹⁰¹⁻¹⁰³ There is currently a paucity of research on the effects of COCs on cerebrovascular function, particularly cerebral autoregulation, in migraineurs. If COCs are shown to affect alter or impair cerebral autoregulation, this may render female migraineurs more susceptible to ischaemic stroke if their cerebral perfusion pressure falls below their cerebral autoregulation limits. Further studies are needed to investigate the effect of COCs on cerebrovascular function in migraineurs.

Migraine prophylactic medications and cerebrovascular function

Beta-blockers (e.g. propranolol, atenolol), calcium channel blockers (e.g. nimodipine) and angiotensin II receptor blockers (e.g. candesartan) are vasoactive antihypertensive medications^{104,105} that have been shown to reduce the risk of stroke in patients with hypertension compared to placebo.¹⁰⁶ They are also used for migraine prophylaxis but there is limited evidence on effects of these medications on cerebrovascular function in migraineurs. Beta-blockers are less effective than calcium channel blockers and angiotensin II receptor blockers for reducing the risk of cerebrovascular disease in patients with hypertension.¹⁰⁷ While calcium channel blockers and angiotensin II receptor blockers are direct-acting vasodilators, beta-blockers lower blood pressure by reducing cardiac output; they may in fact inhibit endothelium-dependent vasodilatation. This difference in vasoactive properties may explain why they are not as effective at reducing risk of cerebrovascular disease. Additionally, in a recent meta-analysis, Webb et al. found that vasodilators such as calcium channel blockers were able to significantly increase CVR to hypercapnia and reduce PI when compared to non-vasodilator medications (such as beta blockers) or placebo. This is particularly interesting, given our findings of lower CVR to hypercapnia and higher PI in migraineurs compared to controls.¹⁰⁷ However, findings from the meta-analyses by Webb et al. may have been limited by the heterogeneous populations and heterogeneous drug classes. Nonetheless, future studies should investigate whether the use of vasodilator medications in migraine prophylaxis is associated with improvements in cerebrovascular function and reduced risk of cerebrovascular disease, i.e. stroke, in migraineurs.

Limitations

We acknowledge that this systematic review and metaanalyses may have some limitations. Firstly, whilst every effort was made to capture all articles of relevance for this review and meta-analysis, some articles may have inadvertently been missed. Secondly, 30 of the 70 studies identified were not able to be included in the meta-analyses due to incomplete or incomparable data, which meant that the findings from the metaanalysis for each measure of cerebrovascular function might have been over- or under-estimated. Thirdly, all the studies included in the meta-analyses used TCD ultrasound to assess cerebrovascular function; however, TCD ultrasound is limited by its inability to assess cerebrovascular function in specific brain regions due to its low spatial resolution.¹⁰⁸ Therefore, we are unable to identify specific brain regions associated with the cerebrovascular abnormalities detected by the meta-analyses. Fourthly, findings from this review may be limited by the heterogeneity between studies. All the meta-analyses, except PI in the posterior circulation and the subgroup analyses for chronic and episodic migraineurs, had high statistical heterogeneity. It is interesting to note that statistical heterogeneity was often higher in the migraine with aura subgroup than other subgroups; this high heterogeneity may have been due to differences in aura status (rare aura vs. frequent aura). Statistical heterogeneity remained high after subgroup analysis, suggesting that there may be additional contributors to heterogeneity such as differences in the vascular risk profile (i.e. smoking, type 2 diabetes mellitus and hypertension) of participants included in the studies. Smoking, diabetes and hypertension have been shown to impair cerebrovascular function.¹⁰⁹ Most studies excluded participants with these vascular risk factors. However, the studies that did not adjust analyses for the vascular risk profile of migraineurs may have reported poorer cerebrovascular function that was associated with their vascular risk factors as opposed to purely migraine. Gender may also be another source of heterogeneity between the studies included in this review and meta-analysis. Women are three times more likely to suffer from migraine compared to men. This gender disparity may be influenced by the fluctuation of female sex hormones, particularly oestrogen, throughout a woman's reproductive life and especially during menstruation. More than 50% of female migraineurs experience migraine attacks without aura that occur when oestrogen concentrations rapidly decrease prior to menstruation or during ovulation. These migraines are classified as menstrual migraines.¹¹⁰ Additionally, in a study by Nevo et al.,¹¹¹ cerebrovascular function, as assessed by MBFV and cerebrovascular resistance, was found to change between different phases of the menstrual cycle. Therefore, the cerebrovascular function of women included in this review may have been influenced by their menstrual cycle phase (i.e. follicular, ovulation or luteal phase). Additionally, the use of COCs may also be a source of heterogeneity as COCs may increase resting MBFV and therefore may have affected the resting MBFV findings.

Laterality of cerebrovascular function assessment may be another source of heterogeneity; some studies assessed cerebrovascular function unilaterally, others bilaterally. Approximately 15% of migraineurs report migraine pain to occur on the same side for at least 90% of their migraine attacks.¹¹² Therefore, migraineurs who experience these 'side-locked' migraines may have differences in cerebrovascular function between the right and left hemispheres. Most studies did not report whether the migraineurs in their study experienced lateralised migraine and therefore did not compare the migraine pain side to the non-migraine pain side. Additionally, we were not able to conduct a separate analysis for studies that compared the cerebrovascular function of the migraine pain side to the non-migraine pain side and therefore we may have not captured the complete picture of the cerebral haemodynamics in migraineurs.

Conclusion

This systematic review and meta-analysis was conducted to investigate whether migraine is associated with altered cerebrovascular function. Despite high statistical heterogeneity, findings from the meta-analyses indicate that migraineurs have altered cerebrovascular function, as represented by a higher resting MBFV, higher PI and lower CVR to hypercapnia in the posterior circulation and higher resting MBFV in the anterior circulation. The higher PI and lower CVR to hypercapnia in the posterior circulation were particularly evident in migraineurs without aura, whereas higher resting MBFV in the anterior circulation was particularly evident in migraineurs with aura. Our findings of altered cerebrovascular function being predominantly restricted to the posterior circulation suggest that the posterior circulation of migraineurs may be more susceptible to alterations in cerebrovascular funcpossibly due to anatomical variations. tion, Additionally, a complex relationship may exist between altered cerebrovascular function in the posterior cerebral circulation and CSD that partially underlies the pathophysiology of migraine. Future studies should investigate relationships between cerebrovascular function (particularly in the posterior circulation) and migraine and investigate whether normalisation or amelioration of cerebrovascular function is able to alleviate migraine. Additionally, future studies should also investigate the effect of vasoactive migraine prophylactic medications on cerebrovascular function in migraineurs and whether these medications are able to reduce vascular risk in migraineurs.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Supplemental material

Supplemental material for this article is available online.

References

- Organisation WH. Headache disorders, https://www.wh o.int/news-room/fact-sheets/detail/headache-disorders (2016, accessed 1 September 2020).
- Woldeamanuel YW and Cowan RP. Migraine affects 1 in 10 people worldwide featuring recent rise: a systematic review and meta-analysis of community-based studies involving 6 million participants. *J Neurol Sci* 2017; 372: 307–315.
- Victoria So. Headache migraine, https://www.betterh ealth.vic.gov.au/health/ConditionsAndTreatments/h eadache-migraine (2018, accessed 1 September 2020)
- Medicine USNLo. Migraine, https://medlineplus.gov/ migraine.html (2018, accessed 1 September 2020)
- 5. Society IH. 1.3 Chronic migraine, 2019.
- May A and Goadsby PJ. The trigeminovascular system in humans: pathophysiologic implications for primary headache syndromes of the neural influences on the cerebral circulation. J Cereb Blood Flow Metab 1999; 19: 115–127.
- Malhotra R. Understanding migraine: potential role of neurogenic inflammation. *Ann Indian Acad Neurol* 2016; 19: 175–182.
- Rajendran P, Rengarajan T, Thangavel J, et al. The vascular endothelium and human diseases. *Int J Biol Sci* 2013; 9: 1057–1069.
- Sacco S, Ripa P, Grassi D, et al. Peripheral vascular dysfunction in migraine: a review. J Headache Pain 2013; 14: 80.
- Pretnar-Oblak J, Sabovic M and Zaletel M. Associations between systemic and cerebral endothelial impairment determined by cerebrovascular reactivity to L-arginine. *Endothelium* 2007; 14: 73–80.
- Perko D, Pretnar-Oblak J, Šabovič M, et al. Associations between cerebral and systemic endothelial function in migraine patients: a post-hoc study. *BMC Neurol* 2011; 11: 146.
- Rajan R, Khurana D and Lal V. Interictal cerebral and systemic endothelial dysfunction in patients with migraine: a case-control study. *J Neurol Neurosurg Psychiatry* 2015; 86: 1253–1257.
- Ornello R, Frattale I, Caponnetto V, et al. Cerebral vascular reactivity and the migraine-stroke relationship: a narrative review. *J Neurol Sci* 2020; 414: 116887.
- Higgins JPT, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. *BMJ* 2003; 327: 557–560.
- Duval S and Tweedie R. Trim and fill: a simple funnelplot-based method of testing and adjusting for publication bias in meta-analysis. *Biometrics* 2000; 56: 455–463.
- Podgorac A, Petrusic I, Radojicic A, et al. Breath holding index in episodic primary headaches. *VSP* 2018; 75: 347–351.
- 17. Karacay Ozkalayci S, Nazliel B, Batur Caglayan HZ, et al. Cerebral blood flow velocity in migraine and

chronic tension-type headache patients. *J Pain Res* 2018; 11: 661–666.

- Choi HA, Mj L and Chung CS. Cerebral endothelial dysfunction in reversible cerebral vasoconstriction syndrome: a case-control study. *J Headache Pain* 2017; 18: 29.
- 19. Akgun H, Tasdemir S and Ulas UH. Reduced breath holding index in patients with chronic migraine. *Acta Neurol Belg* 2015; 115: 323–327.
- Fabjan A, Bajrovic FF, Musizza B, et al. Study of neurovascular coupling during cold pressor test in patients with migraine. *Cephalalgia* 2015; 35: 692–701.
- Karadas O, Gul HL, Ozturk B, et al. The effects of topiramate therapy on cerebral metabolism in migraine with aura patients. *Turk Neurosurg* 2014; 24: 704–709.
- Quirico PE, Allais G, Ferrando M, et al. Effects of the acupoints PC 6 neiguan and LR 3 taichong on cerebral blood flow in normal subjects and in migraine patients. *Neurol Sci* 2014; 35: 129–S133.
- Reinhard M, Schork J, Allignol A, et al. Cerebellar and cerebral autoregulation in migraine. *Stroke* 2012; 43: 987–993.
- Perko D, Pretnar-Oblak J, Sabovic M, et al. Cerebrovascular reactivity to l-arginine in the anterior and posterior cerebral circulation in migraine patients. *Acta Neurol Scand* 2011; 124: 269–274.
- Min JH, Kwon HM and Nam H. The effect of propranolol on cerebrovascular reactivity to visual stimulation in migraine. *J Neurol Sci* 2011; 305: 136–138.
- El-Khawas HM, Shalash AS, Said AM, et al. Multimodal visual functions and cerebrovascular reactivity in migraine patients between attacks. *Egypt J Neurol Psychiatr Neurosurg* 2010; 47: 655–664.
- Reinhard M, Wehrle-Wieland E, Roth M, et al. Preserved dynamic cerebral autoregulation in the middle cerebral artery among persons with migraine. *Exp Brain Res* 2007; 180: 517–523.
- Arjona A, de Torres LAP, Serrano-Castro PJ, et al. A transcranial Doppler study in interictal migraine and tension-type headache. *J Clin Ultrasound* 2007; 35: 372–375.
- Nedeltchev K, Arnold M, Schwerzmann M, et al. Cerebrovascular response to repetitive visual stimulation in interictal migraine with aura. *Cephalalgia* 2004; 24: 700–706.
- Dora B, Balkan S and Tercan E. Normalization of high interictal cerebrovascular reactivity in migraine without aura by treatment with flunarizine. *Headache* 2003; 43: 464–469.
- Thomaides T, Karagounakis D, Spantideas A, et al. Transcranial Doppler in migraine attacks before and after treatment with oral zolmitriptan or sumatriptan. *Headache* 2003; 43: 54–58.
- 32. Dora B and Balkan S. Exaggerated interictal cerebrovascular reactivity but normal blood flow velocities in migraine without aura. *Cephalalgia* 2002; 22: 288–290.
- Chernyshev OY, Vein AM, Mathew NT, et al. Blood flow velocity and pulsatility index differences in patients with unilateral migraine. *Headache* 2001; 41: 704–709.

- Fiermonte G, Annulli A and Pierelli F. Transcranial Doppler evaluation of cerebral hemodynamics in migraineurs during prophylactic treatment with flunarizine. *Cephalalgia* 1999; 19: 492–496.
- Kastrup A, Thomas C, Hartmann C, et al. Cerebral blood flow and CO2 reactivity in interictal migraineurs: a transcranial Doppler study. *Headache* 1998; 38: 608–613.
- Heckmann JG, Hilz MJ, Katalinic A, et al. Myogenic cerebrovascular autoregulation in migraine measured by stress transcranial Doppler sonography. *Cephalalgia* 1998; 18: 133–137.
- Totaro R, Marini C, De Matteis G, et al. Cerebrovascular reactivity in migraine during headache-free intervals. *Cephalalgia* 1997; 17: 191–194.
- Silvestrini M, Matteis M, Troisi E, et al. Cerebrovascular reactivity in migraine with and without aura. *Headache* 1996; 36: 37–40.
- Piccini P, Pavese N, Palombo C, et al. Transcranial doppler ultrasound in migraine and tension-type headache after apomorphine administration – double-blind crossover versus placebo study. *Cephalalgia* 1995; 15: 399–403.
- Fiermonte G, Pierelli F, Pauri F, et al. Co2 reactivity in migraine with aura and without aura – a transcranial doppler study. *Acta Neurol Scand* 1995; 92: 166–169.
- Abernathy M, Donnelly G, Kay G, et al. Transcranial Doppler sonography in headache-free migraineurs. *Headache* 1994; 34: 198–203.
- Thomsen LL, Iversen HK, Brinck TA, et al. Arterial supersensitivity to nitric-oxide (nitroglycerin) in migraine sufferers. *Cephalalgia* 1993; 13: 395–399.
- Anzola GP, Magoni M and Dalla Volta G. Abnormal photoreactivity in lctal migraine – reversal by sumatriptan. *Headache* 1993; 33: 417–420.
- Rieke K, Gallen CC, Baker L, et al. Transcranial doppler ultrasound and magnetoencephalography in migraine. J Neuroimaging 1993; 3: 109–114.
- Totaro R, Matteis GD, Marini C, et al. Blood-flow in migraine with aura – a transcranial Doppler sonography study. *Headache* 1992; 32: 446–451.
- Haring HP and Aichner F. Hemodynamic-findings in migraine patients on transcranial Doppler sonography. *Wien Klin Wochen* 1992; 104: 620–625.
- Zaletel M, Strucl M, Bajrovi FF, et al. Coupling between visual evoked cerebral blood flow velocity responses and visual evoked potentials in migraneurs. *Cephalalgia* 2005; 25: 567–574.
- Vernieri F, Tibuzzi F, Pasqualetti P, et al. Increased cerebral vasomotor reactivity in migraine with aura: an autoregulation disorder? A transcranial Doppler and near-infrared spectroscopy study. *Cephalalgia* 2008; 28: 689–695.
- Benedittis DG. CBF changes during headache-free periods and spontaneous/induced attacks in migraine with and without aura: a TCD and SPECT comparison study. *J Neurosurg Sci* 1999; 43: 141–147.
- 50. Altamura C, Paolucci M, Brunelli N, et al. Migraineurs with aura present an increased cerebral hemodynamics

in the anterior and posterior circulation compared with stroke patients and controls. *Neurol Sci* 2018; 39: 101–102.

- Altamura C, Paolucci M, Brunelli N, et al. Right-to-left shunts and hormonal therapy influence cerebral vasomotor reactivity in patients with migraine with aura. *PLoS One* 2019; 14: e0220637.
- Gollion C, Nasr N, Fabre N, et al. Cerebral autoregulation in migraine with aura: a case control study. *Cephalalgia* 2019; 39: 635–640.
- Gonzalez-Quintanilla V, Toriello M, Palacio E, et al. Systemic and cerebral endothelial dysfunction in chronic migraine. A case-control study with an active comparator. *Cephalalgia* 2016; 36: 552–560.
- Harer C and von Kummer R. CEREBROVASCULAR co2 reactivity in migraine – assessment by transcranial Doppler ultrasound. J Neurol 1991; 238: 23–26.
- Kastrup A, Thomas C, Hartmann C, et al. No effect of prophylactic treatment with metoprolol on cerebrovascular CO2 reactivity in migraineurs. *Cephalalgia* 1998; 18: 353–357.
- Lee MJ, Cho S, Woo S-Y, et al. Paradoxical association between age and cerebrovascular reactivity in migraine: a cross-sectional study. *J Neurol Sci* 2019; 398: 204–209.
- Silvestrini M, Baruffaldi R, Bartolini M, et al. Basilar and middle cerebral artery reactivity in patients with migraine. *Headache* 2004; 44: 29–34.
- 58. Sousa A, Gc Coelho R and Teixeira R. Cerebrovascular reactivity in migraineurs. *Headache Med* 2011; 2: 10–12.
- 59. Thomas TD, Harpold GJ and Troost BT. Cerebrovascular reactivity in migraineurs as measured by transcranial Doppler. *Cephalalgia* 1990; 10: 95–99.
- Valikovics A, Olah L, Fulesdi B, et al. Cerebrovascular reactivity measured by transcranial Doppler in migraine. *Headache* 1996; 36: 323–328.
- 61. Raichle ME and Plum F. Hyperventilation and cerebral blood flow. *Stroke* 1972; 3: 566–575.
- Thomsen LL, Iversen HK and Olesen J. Increased cerebrovascular pCO2 reactivity in migraine with aura – a transcranial Doppler study during hyperventilation. *Cephalalgia* 1995; 15: 211–215.
- Zwetsloot CP, Caekebeke JFV, Odink J, et al. Vascular reactivity during migraine attacks – a transcranial Doppler study. *Headache* 1991; 31: 593–595.
- 64. Backer M, Hammes M, Sander D, et al. Changes of cerebrovascular response to visual stimulation in migraineurs after repetitive sessions of somatosensory stimulation (acupuncture): a pilot study. *Headache* 2004; 44: 95–101.
- Backer M, Sander D, Hammes MG, et al. Altered cerebrovascular response pattern in interictal migraine during visual stimulation. *Cephalalgia* 2001; 21: 611–616.
- Thie A, Carvajal-Lizano M, Schlichting U, et al. Tests of cerebrovascular reactivity in migraine – a transcranial Doppler study. *J Neurol* 1992; 239: 338–342.
- Wolf ME, Jager T, Bazner H, et al. Changes in functional vasomotor reactivity in migraine with aura. *Cephalalgia* 2009; 29: 1156–1164.

- Zaletel M and In M. Neurovascular coupling during ageing. Zdravniski Vestnik Slovenian Med J 2008; 77: II65–II70.
- 69. MüLler M and Marziniak M. The linear behavior of the system middle cerebral artery flow velocity and blood pressure in patients with migraine lack of autonomic control? *Stroke* 2005; 36: 1886–1890.
- Wallasch TM, Beckmann P and Kropp P. Cerebrovascular reactivity during the valsalva maneuver in migraine, tension-type headache and medication overuse headache. *Funct Neurol* 2011; 26: 223–227.
- Datta R, Aguirre GK, Hu S, et al. Interictal cortical hyperresponsiveness in migraine is directly related to the presence of aura. *Cephalalgia* 2013; 33: 365–374.
- Hodkinson DJ, Veggeberg R, Wilcox SL, et al. Primary somatosensory cortices contain altered patterns of regional cerebral blood flow in the interictal phase of migraine. *PLoS One* 2015; 10: e0137971.
- 73. Hu B, Yu Y, Dai YJ, et al. Multi-modal MRI reveals the neurovascular coupling dysfunction in chronic migraine. *Neuroscience* 2019; 419: 72–82.
- Loehrer E, Vernooij MW, van der Lugt A, et al. Migraine and cerebral blood flow in the general population. *Cephalalgia* 2015; 35: 190–198.
- Zhang Q, Datta R, Detre JA, et al. White matter lesion burden in migraine with aura may be associated with reduced cerebral blood flow. *Cephalalgia* 2017; 37: 517–524.
- 76. Arkink EB, Bleeker EJW, Schmitz N, et al. Cerebral perfusion changes in migraineurs: a voxelwise comparison of interictal dynamic susceptibility contrast MRI measurements. *Cephalalgia* 2012; 32: 279–288.
- 77. Ances BM and Detre JA. Perfusion changes with photic stimulation during two phases of the menstrual cycle: a pilot study comparing controls and true menstrual migraine patients. *Cephalalgia* 2003; 23: 907–913.
- Chen ZY, Chen XY, Liu MY, et al. Evaluation of gray matter perfusion in episodic migraine using voxel-wise comparison of 3D pseudo-continuous arterial spin labeling. *J Headache Pain* 2018; 19: 1–8.
- Akin A, Bilensoy D, Emir UE, et al. Cerebrovascular dynamics in patients with migraine: near-infrared spectroscopy study. *Neurosci Lett* 2006; 400: 86–91.
- Schytz HW, Ciftci K, Akin A, et al. Intact neurovascular coupling during executive function in migraine without aura: interictal near-infrared spectroscopy study. *Cephalalgia* 2010; 30: 457–466.
- Meyer JS, Terayama Y, Konno S, et al. Age-related cerebrovascular disease alters the symptomatic course of migraine. *Cephalalgia* 1998; 18: 202–208.
- Facco E, Munari M, Baratto F, et al. Regional cerebral blood flow (rCBF) in migraine during the interictal period. Different rCBF patterns in patients with and without aura. *Cephalalgia* 1996; 16: 161–168.
- Levine SR, Welch KMA, Ewing JR, et al. Asymmetric cerebral blood-flow patterns in migraine. *Cephalalgia* 1987; 7: 245–248.

- Cheng MH, Wen SL, Zhou HJ, et al. Evaluation of headache and regional cerebral flood flow in patients with migraine. *Clin Nucl Med* 2013; 38: 874–877.
- Mirza M, Tutuş A, Erdoğan F, et al. Interictal SPECT with tc-99m HMPAO studies in migraine patients. *Acta Neurol Belg* 1998; 98: 190–194.
- Altamura C, Paolucci M and Vernieri F. Migraine, endothelium, hemodynamics. *Neurol Sci* 2018; 39: 87–89.
- Rivera-Lara L, Zorrilla-Vaca A, Geocadin RG, et al. Cerebral autoregulation-oriented therapy at the bedside a comprehensive review. *Anesthesiology* 2017; 126: 1187–1199.
- King A, Serena J, Bornstein NM, et al. Does impaired cerebrovascular reactivity predict stroke risk in asymptomatic carotid stenosis? A prospective substudy of the asymptomatic carotid emboli study. *Stroke* 2011; 42: 1550–1555.
- Sacco S, Ornello R, Ripa P, et al. Migraine and hemorrhagic stroke: a meta-analysis. *Stroke* 2013; 44: 3032–3038.
- 90. Mahmoud AN, Mentias A, Elgendy AY, et al. Migraine and the risk of cardiovascular and cerebrovascular events: a meta-analysis of 16 cohort studies including 1 152 407 subjects. *BMJ Open* 2018; 8: e020498.
- Spector JT, Kahn SR, Jones MR, et al. Migraine headache and ischemic stroke risk: an updated meta-analysis. *Am J Med* 2010; 123: 612–624.
- Sacco S and Kurth T. Migraine and the risk for stroke and cardiovascular disease. *Curr Cardiol Rep* 2014; 16: 524.
- Bush AM, Borzage MT, Choi S, et al. Determinants of resting cerebral blood flow in sickle cell disease. *Am J Hematol* 2016; 91: 912–917.
- 94. Cucchiara B, Wolf RL, Nagae L, et al. Migraine with aura is associated with an incomplete circle of willis: results of a prospective observational study. *PLoS One* 2013; 8: e71007.
- Bugnicourt JM, Garcia PY, Peltier J, et al. Incomplete posterior circle of Willis: a risk factor for migraine? Research submission. *Headache* 2009; 49: 879–886.
- 96. Chatzizisis YS, Coskun AU, Jonas M, et al. Role of endothelial shear stress in the natural history of coronary atherosclerosis and vascular remodeling. Molecular, cellular, and vascular behavior. J Am Coll Cardiol 2007; 49: 2379–2393
- Murinova N, Krashin DL and Lucas S. Vascular risk in migraineurs: interaction of endothelial and cortical excitability factors. *Headache* 2014; 54: 583–590.
- Cui Y, Kataoka Y and Watanabe Y. Role of cortical spreading depression in the pathophysiology of migraine. *Neurosci Bull* 2014; 30: 812–822.

- 99. Sacco S, Merki-Feld GS, Ae KL, et al. Hormonal contraceptives and risk of ischemic stroke in women with migraine: a consensus statement from the European Headache Federation (EHF) and the European Society of Contraception and reproductive health (ESC). J Headache Pain 2017; 18: 1–20.
- 100. Ornello R, Canonico M, Merki-Feld GS, et al. Migraine, low-dose combined hormonal contraceptives, and ischemic stroke in young women: a systematic review and suggestions for future research. *Expert Rev* 2020; 20: 313–317.
- Nichols M, Robinson G, Bounds W, et al. Effect of four combined oral contraceptives on blood pressure in the pill-free interval. *Contraception* 1993; 47: 367–376.
- Abramson BL and Melvin RG. Cardiovascular risk in women: focus on hypertension. *Can J Cardiol* 2014; 30: 553–559.
- Barton M and Meyer MR. Postmenopausal hypertension: mechanisms and therapy. *Hypertension* 2009; 54: 11–18.
- 104. Chen GJ and Yang MS. The effects of calcium channel blockers in the prevention of stroke in adults with hypertension: a meta-analysis of data from 273,543 participants in 31 randomized controlled trials. *PLoS One* 2013; 8: e57854.
- 105. Lu GC, Cheng JW, Zhu KM, et al. A systematic review of angiotensin receptor blockers in preventing stroke. *Stroke* 2009; 40: 3876–3878.
- Dahlof B. Prevention of stroke: new evidence. *Eur Heart J* 2009; 11: F33–F38.
- 107. Webb AJS. Effects of vasodilating medications on cerebral haemodynamics in health and disease: systematic review and meta-analysis. J Hypertension 2019; 37: 1119–1125.
- 108. Leoni RF, Mazzetto-Betti KC, Silva AC, et al. Assessing cerebrovascular reactivity in carotid stenoocclusive disease using MRI BOLD and ASL techniques. *Radiol Res Pract* 2012; 2012: 268483.
- Silvestrini M, Troisi E, Matteis M, et al. Effect of smoking on cerebrovascular reactivity. J Cereb Blood Flow Metab 1996; 16: 746–749.
- 110. Sacco S, Ricci S, Degan D, et al. Migraine in women: the role of hormones and their impact on vascular diseases. *J Headache Pain* 2012; 13: 177–189.
- Nevo O, Soustiel JF and Thaler I. Cerebral blood flow is increased during controlled ovarian stimulation. *Am J Physiol* 2007; 293: H3265–H3269.
- Loder E, Weizenbaum E and Giddon D. Migraine pain location and measures of healthcare use and distress: an observational study. *Pain Res Manag* 2018; 2018: 6157982.